Pathogenicity, functional significance and clinical phenotype of mismatch repair gene MSH2 variants found in cancer patients by Ollila, Saara
1
Pathogenicity, functional significance and clinical








To be publicly discussed, with the permission of
The Faculty of Biosciences, University of Helsinki,
in the auditorium 1041 of the Biocenter II, Viikinkaari 5, Helsinki,
on the 19th of September 2008 at 12 o’clock noon.
2
Supervisor Docent Minna Nyström
Department of Biological and Environmental Sciences
University of Helsinki, Finland
Reviewers Professor Klaus Elenius
Department of Medical Biochemistry and Molecular Biology
University of Turku, Finland
Docent Helmut Pospiech
Leibniz Institute for Age Research
Fritz Lipmann Institute, Jena, Germany
Opponent Professor Torben F. Ørntoft
Department of Clinical Biochemistry




Helsinki 2008, Helsinki University Printing House
3








REVIEW OF THE LITERATURE .................................................................................13
Cancer .................................................................................................................13
Cancer genetics ................................................................................................ 14
Oncogenes and tumour suppressor genes.......................................................... 14
Hereditary cancer ............................................................................................. 15
DNA maintenance ...............................................................................................17
Origins of mutagenesis..................................................................................... 17
DNA repair pathways....................................................................................... 17
Mismatch repair..................................................................................................22
MMR in Escherichia coli ................................................................................. 23
MMR in eukaryotes ......................................................................................... 24
Hereditary nonpolyposis colorectal cancer..........................................................31
Genetics of HNPCC ......................................................................................... 31
Clinical characteristics of HNPCC patients ...................................................... 33
Muir-Torre syndrome....................................................................................... 35
Nontruncating mutations in HNPCC ...................................................................35
Frequency of nontruncating mutations in MMR genes ..................................... 35
Functional analysis of nontruncating MMR gene variants ................................ 36
AIMS OF THE PRESENT STUDY ...............................................................................39
MATERIALS AND METHODS...................................................................................40
MSH2 mutations and associated families (I-IV)...................................................40
Functional assays (I-IV) .......................................................................................43
Protein expression and coimmunoprecipitation (I-IV) ...................................... 43
Protein purification (III-IV).............................................................................. 45
Mismatch repair assays (I-IV) .......................................................................... 46
Bandshift assays (III-IV).................................................................................. 49
5
RESULTS ..................................................................................................................51
Effects of the studied mutations on MSH2 expression, purification and interaction
with MSH6 (II-IV)........................................................................................... 51
Effects of MSH2 mutations on mismatch repair and binding and release of
mismatches (I-IV) ............................................................................................ 52
Correlation between the functional assays and clinical phenotypes of mutation
carriers (I-IV)................................................................................................... 57
DISCUSSION ...........................................................................................................59
MSH2 L187P and C697F predispose to HNPCC and MTS .............................. 60
No evidence for MSH2 N127S and G322D -linked cancer predisposition ........ 61
The majority of the studied MSH2 variants inactivated MMR.......................... 62
Decreased protein expression was associated with MMR deficiency in N-terminal
MSH2 missense mutations ............................................................................... 62
Pathogenic mutations in the ATPase domain mostly interfered with mismatch
binding or release............................................................................................. 64
MSH2 G674A displayed reduced capability to interact with MSH6 ................. 65
Phenotypic characteristics of the mutation carriers correlated with the
functional data ................................................................................................. 66
IHC as a screening tool for HNPCC ................................................................. 67






LIST OF ORIGINAL PUBLICATIONS
I Ollila  S,  Fitzpatrick  R,  Sarantaus  L,  Kariola  R,  Ambus  I,  Velsher  L,  Hsieh  E,
Andersen MK, Raevaara TE, Gerdes AM, Mangold E, Peltomäki P, Lynch HT,
Nyström M. The importance of functional testing in the genetic assessment of
Muir-Torre syndrome, a clinical subphenotype of HNPCC. Int J Oncol. 2006
Jan;28(1):149-53.
II Ollila S, Sarantaus L, Kariola R, Chan P, Hampel H, Holinski-Feder E, Macrae F,
Kohonen-Corish M, Gerdes AM, Peltomäki P, Mangold E, de la Chapelle A,
Greenblatt M, Nyström M. Pathogenicity of MSH2 missense mutations is typically
associated with impaired repair capability of the mutated protein.
Gastroenterology. 2006 Nov;131(5):1408-17.
III Ollila S, Dermadi Bebek D, Greenblatt M, Nyström M. Uncertain pathogenicity of
MSH2 variants N127S and G322D challenges their classification. Int J Cancer
2008 Aug 1;123(3):720-4.
IV  Ollila S, Dermadi Bebek D, Jiricny J, Nyström M. Mechanisms of pathogenicity in






ATR ATM and Rad3-related
APC Adenomatous polyposis coli
BER Base excision repair
cDNA Complementary DNA
CHK1, 2 Checkpoint kinase 1, 2
CRC Colorectal cancer
CSA, B Cockayne syndrome A, B
C-terminus Carboxy terminus
DSBR Double-strand break repair
dsDNA Double-stranded DNA
EC Endometrial carcinoma
E. coli Escherichia coli
EXO1 Exonuclease 1
FAP Familial adenomatous polyposis coli
FPLC Fast protein liquid chromatography
GGR Global genome repair
HNPCC Hereditary nonpolyposis colorectal cancer
IDL Insertion / deletion loop
IHC Immunohistochemistry
InSiGHT International Society for Gastrointestinal Hereditary Tumors
IR Ionizing radiation
LOH Loss of heterozygosity
NE Nuclear protein extract
NER Nucleotide excision repair
NHEJ Non-homologous end joining
Ni-NTA Nickel-nitrilotriacetic acid








PCNA Proliferating cell nuclear antigen
PMS1, 2 Human postmeiotic segregation increased homolog 1, 2
PMSF Phenylmethylsulfonyl fluoride
RFC Replication factor C
RPA Replication protein A
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
Sf 9 Spodoptera frugiperda 9
SIFT Sorting intolerant from tolerant
SNP Single nucleotide polymorphism
ssDNA Single-stranded DNA
TCR Transcription-coupled repair





Hereditary nonpolyposis colorectal cancer (HNPCC) is a hereditary cancer syndrome,
which manifestates with high penetrance in early middle age, mainly with colorectal and
endometrial tumours. Susceptibility for HNPCC is dominantly inherited with germline
defects in the mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2. While a
truncating mutation in one of these genes leads to deficient MMR, thereby promoting
genetic instability and tumour formation, a nontruncating mutation can either be a
completely neutral variation or lead to a highly increased cancer risk and HNPCC. The
phenotypic effects of nontruncating mutations are impossible to predict based on genetic
evidence alone. The correct determination of the pathogenicity of different mutations is,
however, very important, as the verification of the causative mutation enables genetic
counselling and surveillance of mutation carriers, which has been shown to lead to
significantly lowered mortality.
The most frequent nontruncating mutations are missense mutations, which alter
only one amino acid in the protein. Unlike in MLH1, where missense mutations have been
characterised extensively, functional studies on nontruncating MSH2 mutations are rarer.
MSH2 is the second most commonly mutated HNPCC susceptibility gene and defects in it
account for 39% of all identified HNPCC mutations. Seventeen percent of all identified
MSH2 variations  are  of  the  missense  type.  The  aim  of  this  PhD  thesis  was  to  gather
functional evidence on the pathogenicity of patient-derived nontruncating MSH2 variants.
We assessed the functionality of 18 mutations and correlated the site of the mutation to the
biochemical and phenotypic effects of the mutated protein. The proteins corresponding to
the original genetic MSH2 variants were expressed and purified. The expression level,
MMR efficiency, interaction with MSH6, mismatch binding, and mismatch release
capabilities of the protein variants were studied. The results of the functional assays were
compared to the clinical characteristics of the mutation carriers.
Twelve of the studied eighteen mutations were found to exhibit severe defects in
the functional assays, supporting the hypothesis that these mutations were the underlying
cause of the cancer phenotype in mutation carriers. In addition, two mutations reduced but
did not abolish the function of the protein. Four mutations showed no or only minor defect
in the assays. The characterisation of the biochemical defects revealed different
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mechanisms  through  which  the  pathogenic  effects  were  mediated.  The  majority  of  the
MMR-deficient mutations which were located in the amino-terminal domains of the
MSH2 polypeptide demonstrated defects in the protein expression level. Most of the
carboxy-terminal mutations, situated in the ATPase domain, had an impact on the ability
of the protein to bind or release mismatched DNA. When comparing the biochemical data
to the tumour phenotype, a significant correlation between the functional deficiency in
vitro and lack of expression of the corresponding protein in the tumour tissue was
observed.
The analyses demonstrated that the location of the mutation may affect not only
the biochemistry of MMR but also the phenotype of MSH2 mutation carriers. This study
significantly contributed to the knowledge of MSH2-associated HNPCC tumorigenesis,
thereby facilitating the diagnostics and counselling of the associated families. In addition,
the study confirmed and supplemented the prevailing knowledge of the biochemical
functions and characteristics of different MSH2 domains.
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INTRODUCTION
In 1993, the molecular background of a familially clustered cancer syndrome, hereditary
nonpolyposis colorectal cancer (HNPCC), was revealed to be associated with germline
mutations in genes encoding DNA mismatch repair (MMR) proteins (Peltomäki et al.
1993a). Due to the great clinical importance of HNPCC, this breakthrough led to intense
research on MMR. To date, MMR is well characterised and germline defects in four
MMR genes, MLH1, MSH2, MSH6 and PMS2, have been shown to predispose to HNPCC
(Peltomäki 2005, Woods et al. 2007).
Tumorigenesis in HNPCC results from genetic instability, which reflects the loss
of the postreplicative DNA repair activity displayed by MMR. This can be observed as the
microsatellite instability (MSI), which is the hallmark of MMR-deficient tumours
(Aaltonen et al. 1993). The most typical tumours in HNPCC syndrome are tumours of the
colon, rectum and endometrium, whereas other types, such as hepatobiliary, small bowel,
gastric, ovarian and brain cancers occur more rarely yet being more frequent than in the
general population (Watson, Riley 2005). The average age of cancer onset in HNPCC is
about 45 years, whereas most sporadic colorectal cancers have a typical onset some
twenty years later (Lynch, de la Chapelle 1999a). HNPCC has a very high penetrance, and
the lifetime risk of developing cancer in MLH1 and MSH2 mutation carriers is close to
100%. The penetrance is somewhat lower in MSH6 and PMS2 mutation carriers
(Peltomäki 2005).
Thanks to intensive research and highly developed cancer surveillance systems, a
large  proportion  of  the  HNPCC related  malignancies,  especially  the  colorectal  ones,  can
be removed already at an early stage. Thus, in countries, such as Finland, where genetic
counselling and cancer surveillance are efficient, HNPCC-related mortality is low
(Mecklin et al. 2007). However, the efficient screening and counselling of HNPCC
patients can only be applied if the predisposing mutation is characterised.
There are several factors that make HNPCC diagnostics challenging. Colorectal
cancer (CRC) is the third most common cancer in the Western world. It accounts for 10%
of all diagnosed cancers, thus affecting up to 150 000 people in the US and 2 500 people
in Finland in a year (Jemal et al. 2008, www.cancerregistry.fi). HNPCC accounts for only
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2 – 3% of all CRC cases (Lynch, de la Chapelle 2003, Salovaara et al. 2000). There are no
clear clinical features separating hereditary from sporadic CRC. Traditionally, HNPCC
diagnostics has been done using information on the familial clustering and the early age at
onset as criteria (Vasen et al. 1991, Vasen et al. 1999). This approach, however, leaves
many HNPCC cases unnoticed, when information about family members is lacking or
when  the  family  is  too  small  to  fulfil  the  diagnostic  criteria.  MSI  and
immunohistochemistry (IHC) studies on genetic instability and MMR protein expression
in  the  tumour,  respectively,  give  indications  as  to  the  MMR  defect,  but  as  such  do  not
provide evidence of its heredity. Therefore, mutational analysis is a prerequisite for
reliable diagnostics. The considerable sizes of the four predisposing genes make
mutational analysis laborious. Furthermore, all genetic variations found in MMR genes are
not associated with cancer predisposition, creating further challenges to HNPCC
diagnostics.
Missense mutations, which lead to single amino acid alterations, and small in-
frame insertions and deletions, may change the structure of the protein only slightly and
associate with functional MMR and no increased cancer predisposition. Alternatively,
they can inactivate MMR and lead to HNPCC. When reliable data of the co-segregation of
the cancer phenotype and genetic variation is not available, the pathogenicity and
phenotypic outcome of a nontruncating variant is impossible to predict. In those cases,
only functional analysis can aid in determining the pathogenicity of the mutation.
The aim of this PhD thesis was to study the pathogenicity, functional significance
and clinical phenotype of nontruncating variants in the MSH2 gene. MSH2 is the second
most common predisposing gene for HNPCC, and the studied mutations were found from
cancer patients. Our findings demonstrate that most of the studied mutations indeed affect
MMR, and that the pathogenicity of the mutation is mediated through different
mechanisms, depending on the location of the mutation in the MSH2 protein. The results
of this study facilitate the genetic counselling of all carriers of the studied mutations,
especially those whose pathogenicity was ascertained by our work, confirming the
HNPCC diagnosis.
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REVIEW OF THE LITERATURE
CANCER
The human body is composed of nearly 1014 cells.  In  order  to  maintain  the  appropriate
homeostasis of an individual, the differentiation, division and death of all those cells must
occur in a highly controlled manner, and failures in this regulation may lead to the
formation  of  tumours.  Tumours  are  characterised  by  uncontrolled  growth  of  cells,
resulting in cell division at an abnormal time or rate or in an abnormal space. Cancer is a
group of diseases characterised by malignant tumours, which are differentiated from the
benign ones by their ability to invade adjacent tissues.
Cancer is the second most prevalent cause of death in Western countries. It
develops slowly and thus affects mainly elderly people. Therefore, cancer incidence is
higher in countries where life expectancy in general is high. In Finland, about 27 000
cancers were diagnosed in the year 2006 (Finnish Cancer Registry,
www.cancerregistry.com), and the estimate number of cancers in the US for 2008 is
nearly 1 500 000 (Jemal et al. 2008). In males, the most prevalent cancers occur in the
prostate, lung or bronchus, colorectum, and urinary bladder. In females, breast cancer is
the most prevalent, followed by colorectal, lung and uterine cancer (Jemal et al. 2008,
American Cancer Society, www.cancer.org). The same cancer types are prevalent in all
Western countries. In total, more than one-third of the population develops a cancer at
some point in life, and the general survival rate 5 years from cancer diagnosis is about
66%. (Jemal et al. 2008, www.cancer.org.) Because of its high incidence, and vast effects
on society both in the form of human suffering and costs to health care, cancer research is
one of the most intensive focuses of study in modern biology. The aim of the research is to
understand  the  processes  of  cancer  development  and,  thereafter,  be  able  to  diagnose  the




Cancer in general is characterised as atypical cell growth resulting from abnormalities in
cellular regulation. Most of the abnormalities are consequences of alterations in DNA, the
molecule which holds the information on how the cell is built and maintained. Cancer
results from the accumulation of defects in genes which regulate cellular homeostasis and
growth. For a cell population to become cancerous, it needs to fulfil several requirements
which are not met by normal cells: self-sufficiency in growth signals, non-responsiveness
to anti-growth signals, avoidance of apoptosis and senescence, formation of vasculature,
and capacity for tissue invasion and metastasis (Hanahan, Weinberg 2000). Furthermore,
evading the body’s own immune response has in recent years been show to be an
important step in tumour pathogenesis (Drake, Jaffee & Pardoll 2006). Fulfilling all these
conditions requires that several genetic changes take place. Therefore, malignant
transformation is believed to occur sequentially through a process where certain genetic
alterations give cells a growth advantage, allowing them to expand more efficiently as
compared to normally regulated cells, and subsequently acquire more alterations. This can
be seen as Darwinian evolution in the cell population: the most efficiently growing cells
survive best. (Weinberg, 2007)
Oncogenes and tumour suppressor genes
Genes which participate in tumorigenic processes are divided into two main classes:
oncogenes and tumour suppressor genes. In general, proto-oncogenes possess growth-
promoting effects under normal circumstances. Transformation of proto-oncogenes to
oncogenes can occur through activating mutations, increased expression, or gene
amplification. Thus, oncogenes increase the cell’s growth potential by gene activation.
Their tumour-promoting effect is dominant, already affecting cell growth with one altered
allele. Oncogenes are typically genes which encode players in signal transduction
pathways, such as growth factor receptor tyrosine kinases (e.g. epidermal growth factor
receptors, ErbB1-4), signal transduction molecules (Ras, Raf), transcription factors (Myc)
or anti-apoptotic proteins (Bcl-2). Many oncogenes, such as Src, Ras, and Myc, have been
identified via their viral homologs, which have been found to promote tumorigenesis upon
viral infection (Diehl, Keller & Ignatoski 2007).
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Tumour suppressor genes possess growth-limiting functions. In their case, the growth
advantage is acquired by gene inactivation, and in most cases both alleles need to be
inactivated before the effect takes place. Therefore, their effect in tumour progression is
recessive. Tumour suppressor genes are further divided into so-called gatekeepers, whose
function is to regulate the cell division, and caretakers, which look after the integrity of
DNA. Typical gatekeepers are for example retinoblastoma (Rb) and INK4a, which
regulate the G1-S cell cycle checkpoint; pro-apoptotic genes of the BAX family; and
regulators of growth-promoting molecular pathways, such as adenomatous polyposis coli
(APC) (Sherr 2004). Caretaker genes encode proteins which participate in the maintenance
of DNA. Absence of this action leads to increased mutagenesis and therefore an increased
occurrence of subsequent alterations in proto-oncogenes and tumour suppressors.
Reflecting the importance of DNA integrity, to date over 100 proteins with a role in DNA
maintenance have been described (Christmann et al. 2003), and defects in many of those
are connected to cancer formation. This will be discussed in detail in later chapters.
Hereditary cancer
Despite being considered a disease of the genome, the great majority of cancers are not
hereditary. However, several rare syndromes characterised by the familial inheritance of
cancer predisposition in a (near-) Mendelian manner have been identified. These inherited
cancer syndromes are very important areas of study mainly because of two reasons.
Firstly, identification of the genetic component predisposing to cancer in a family allows
diagnosis and surveillance of the other mutation carriers, and leads to relief from the fear
of a high cancer risk in non-carriers (Aktan-Collan et al. 2000). Secondly, inherited cancer
syndromes provide starting points for understanding the genetic components involved in
the regulatory pathways which, when altered, may contribute to cancer formation. Thus,
information derived from studies concerning hereditary cancers can be applied to the
management of all cancers (Fearon 1997).
In hereditary cancer syndromes, the resulting tumour usually develops at an earlier
age as compared to the corresponding sporadic cancers, reflecting the skipping of one step
in the chain of somatic mutations needed for tumour development. This skip is a result of
a germline alteration, usually in a tumour suppressor gene. The altered gene can
predispose to cancer in a dominant or recessive mode. However, also the dominantly
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inherited cancer syndromes are believed to act in a recessive manner at the cellular level,
elucidating the requirement for a somatic mutation in the second allele. This “second hit” -
hypothesis was first presented in the context of retinoblastoma, a cancer of the eye.
Retinoblastoma is inherited through an inactivating mutation in one allele of the tumour
suppressor gene Rb,  which  plays  an  important  role  in  regulation  of  the  G1-S  cell  cycle
checkpoint. Based on his observations of retinoblastoma patients, Alfred G. Knudson
created his famous model for the formation of a hereditary cancer (Knudson 1971). In the
two-hit hypothesis, Knudson proposed that both copies of the Rb tumour suppressor gene
have to be inactivated in a cell before the cell acquires a growth advantage. In familial
cases, one allele is inactivated already in the germline, and when the second copy is lost
by somatic inactivation, tumorigenesis is initiated. In sporadic retinoblastoma, both alleles
need to be somatically inactivated. Later, this hypothesis has been expanded to many
tumour suppressor-associated cancer syndromes (Knudson 1996).
The most common hereditary cancers associated with germline defects in tumour
suppressor genes are listed in Table 1. The oncogenes associated with familial cancer are
RET, MET, and CDK4, which, when mutated in the germline, predispose to multiple
endocrine neoplasia type 2A and 2B, hereditary papillary renal cell carcinoma, and
familial melanoma syndromes, respectively (Marsh, Zori 2002).
 Table 1. The most common hereditary cancers associated with germline defects in tumour
suppressor genes.  (Fearon 1997, Marsh, Zori 2002)
Gene Syndrome Primary tumour Function of the gene(s)
APC Familial adenomatous polyposis Colorectal cancer -catenin regulation
ATM Ataxia telangiectasia Lymphoma DNA damage response
BLM Bloom's syndrome Solid tumours DNA helicase
BRCA1 Familial breast and ovarian cancer Breast and ovarian cancer DNA damage response
BRCA2 Familial breast cancer Breast cancer DNA damage response
CDKN2 Familial melanoma Melanoma Cell cycle regulation
FANC1-12 Fanconi anemia Leukemia DNA crosslink repair





Colorectal cancer Mismatch repair
NF1 Neurofibromatosis type 1 Neurofibromas RAS regulator




p53 Li-Fraumeni syndrome Sarcomas, breast cancer DNA damage response
PRKAR1A Carney complex syndrome Pituitary adenoma cAMP pathway
PTCH Nevoid basal cell carcinoma syndrome Basal cell skin cancer Hedgehog signalling
receptor
PTEN Cowden disease Breast and thyroid cancer Tyrosine phosphatase
RB1 Familial retinoblastoma Retinoblastoma Cell cycle regulation
SMAD4 Juvenile polyposis coli Colorectal cancer TGF-  signalling mediator
VHL Von Hippel-Lindau syndrome Renal cancer Fibronectin matrix
assembly
WT1 Wilms tumor Paediatric kidney tumours Transcriptional regulation
XPA-G Xeroderma pigmentosum Skin cancer Nucleotide excision repair




If cancer is considered a disease resulting from cumulative genetic alterations, then how
do these alterations come about? DNA, as well as other molecules in the cell, is at all
times exposed to several damaging agents, which alter its chemical features. DNA is the
guidebook for building all other cellular molecules and it exists only in two functional sets
in each diploid cell. Both copies are necessary. DNA molecules are irreplaceable, and
therefore most sensitive to damage. The sources of DNA-damaging agents can be
endogenous, originating from the cell’s own metabolism, or exogenous, deriving from
outside of the body. The most significant source of endogenous DNA damage is reactive
oxygen species, which are unavoidable byproducts of oxidative metabolism. Exogenous
DNA damage is caused e.g. by ionising radiation (IR), such as X-rays or the high-energy
radiation  resulting  from  radioactive  decay,  UV  radiation  from  the  sun,  and  chemical
carcinogens, such as those derived from tobacco smoke or food. These agents cause a
wide variety of chemical modifications in DNA. Importantly, also spontaneous chemical
reactions, such as deaminations, depurinations and depyrimidations take place frequently,
destabilizing DNA even in the absence of any particular genotoxic stress.
In addition to chemical modifications, which alter the structure of DNA bases,
faulty insertions of structurally perfect bases occur rarely but steadily in the course of
DNA replication. Both types of mutagenesis promote tumorigenesis by altering the
properties  of  functionally  important  genes.  Because  of  the  extreme  importance  of  DNA
stablility, and the vast spectrum of lesions which destabilize it, several repair pathways
and damage responses have evolved to maintain the integrity of DNA (Reviewed e.g. in
Rouse, Jackson 2002, Christmann et al. 2003, Hakem 2008). Supporting the idea of
increased mutability leading to cancer formation, inborn defects in many of these DNA
repair systems lead to a predisposition to hereditary cancer syndromes.
DNA repair pathways
Nucleotide excision repair
A link between DNA repair and cancer was first established when it was shown that cells
of xeroderma pigmentosum (XP) patients, who suffered from sensitivity to sunlight and a
predisposition  to  cancer,  were  unable  to  repair  DNA  lesions  after  exposure  to  UV  light
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(Cleaver 1968). The XP syndrome is inherited in an autosomal recessive manner in genes
named XPA-G and V. These XP-associated genes consist of components of a specific
DNA repair system called nucleotide excision repair (NER). NER defects are also
associated with a variety of segmental progeria syndromes, connecting DNA repair
defects not only to cancer but also to ageing (Andressoo, Hoeijmakers & Mitchell 2006).
NER recognises and repairs a variety of DNA adducts, which cause distortions to
the DNA helix, such as UV irradiation-induced pyrimide dimers and 6-4-photoproducts,
and bulky adducts caused by chemical mutagens. NER is functionally divided to two
distinct pathways, transcription-coupled repair (TCR) and global genome repair (GGR)
(Reviewed in Fousteri, Mullenders 2008, Shuck, Short & Turchi 2008). In TCR, the
proteins Cockayne syndrome A (CSA) and CSB are required for lesion recognition, which
occurs when the elongating RNA polymerase II gets blocked at the site of DNA damage.
Therefore, TCR is limited to the template strand of actively transcribed regions of DNA.
In  GGR,  the  lesion  recognition  component  is  hHR23B/XPC,  and  GGR  repairs  DNA
without strand bias. Following lesion recognition, the NER machinery shares the same
components in both subpathways. The transcription factor IIH (TFIIH) complex is
recruited to the site of the lesion and the XPB and XPD helicase subunits of TFIIH
unwind the  DNA.  XPA outlines  the  site  of  repair  and  assembles  the  remaining  essential
NER machinery on the site. The defective strand is incised by endonucleases XPG and
XPF/ERCC1 at the 5’ and 3’ ends of the lesion, respectively, and the resulting gap is filled
by DNA polymerases and the backbone sealed by DNA ligase I. In total, NER reaction
involves over 25 distinct enzymes (Aboussekhra et al. 1995).
Base excision repair
Base excision repair (BER) is mainly responsible for the recognition and correction of
oxidised and alkylated bases, resulting from cellular metabolic events and IR, and the
correction of abasic sites resulting from spontaneous depurination and depyrimidation
events. BER also addresses DNA bases arising from deamination reactions, which for
example  convert  cytosine  into  uracil,  giving  rise  to  C T  /  G A transitions if not
corrected. Furthermore, BER recognises some DNA mispairs, such as G•T mispairs,
which result from the above-mentioned cytosine deamination (Hegde, Hazra & Mitra
2008). The BER machinery is initiated by glycosylases, each of which recognizes a
specific type of DNA lesion. For example, OGG1 and OGG2 recognize oxidised bases,
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TDG detects T and U in T•G and U•G mispairs, UDG uracil, and MYH adenine in 8-oxo-
G•A mispairs. The glycosylases detach the incorrect base from the deoxyribose backbone
of the DNA molecule, leaving behind an abasic site. Abasic site endonuclease (APE) then
cuts the strand to be repaired 5’ from the abasic site, and DNA polymerase  inserts the
correct base to the site of repair. The DNA strand is sealed by DNA ligase. In addition, so-
called long-batch BER, which removes and resynthesizes 4 – 7 bases around the lesion,
has been described (Frosina et al. 1996). Defects in BER are also connected to cancer
predisposition, as biallelic mutations in MYH can lead to multiple colorectal adenomas
and carcinomas (Al-Tassan et al. 2002, Sieber et al. 2003).
Double-strand break repair
DNA double-strand breaks (DSBs) are generated for example by IR or oxidative damage.
They  can  also  form  due  to  the  collapse  of  the  replication  fork  when  the  replication
machinery encounters single-strand breaks or damaged bases. DSBs are a very severe
form  of  DNA  damage,  and  even  one  such  break  can  cause  cell  death  (Rich,  Allen  &
Wyllie 2000). Unrepaired DSBs or incorrect repair leads to chromosome fusions, deletions
and translocations, which are typical rearrangements in cancer cells (Jackson 2002). Two
mechanisms are responsible for double-strand break repair (DSBR): homologous
recombination (HR) and non-homologous end joining (NHEJ).
HR is an error-free repair system, which processes DNA breaks using the intact
identical sister chromatid or, more rarely, the homologous chromosome as the template to
rescue  the  DSB  and  to  construct  an  intact  DNA  molecule.  Therefore,  HR  takes  place
mainly in the S or G2 phases of the cell cycle, when the sister chromatid is available.
Also, HR is believed to account for the processing of most if not all DSBs associated with
replication fork collapse, because in those cases only one free dsDNA end emerges,
making it impossible for the classical NHEJ pathway to repair the lesion (see below).
The MRN complex, consisting of MRE11, Rad50 and NBS1 proteins, is believed
to process the free DNA ends in HR to create single-stranded overhangs, whose ends are
then bound by Rad52 (Stasiak et al. 2000). RPA coats the single-stranded regions; and
Rad51 forms nucleoprotein filaments on ssDNA to promote strand exchange. Rad52 and
Rad54 promote the homology search and strand-exchange events of Rad51-coated ssDNA
with the complementary DNA strand. Strand invasion is followed by branch migration,
gap filling and resolving of the intermediate structures to give rise to two intact DNA
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molecules (reviewed e.g. in Helleday 2003, Li, Heyer 2008). Among the various other
proteins involved in HR are BRCA1 and BRCA2, mutations in which predispose to
familial breast and ovarian cancer (Fackenthal, Olopade 2007).
HR is, in addition to functions in DSBR, also involved in the processing of
intrastrand crosslinks (ICLs), which are detrimental DNA lesions leading to the blockage
of transcription and replication (Dronkert, Kanaar 2001). In response to ICLs, proteins of
the Fanconi Anemia (FA) pathway are important for the initiation of Rad51-mediated HR.
Patients carrying mutations in genes involved in this pathway (altogether 12 identified
FANC genes) are prone to cancers, such as acute myeloid leukemia and squamous cell
carcinoma, and the hallmark of FA patient cells is sensitivity to DNA intrastrand
crosslinking agents, such as Mitomycin C (Patel, Joenje 2007).
The NHEJ pathway is used for DSBR in the G0 and G1 phases of the cell cycle,
when the sister chromatid templates for HR are not available. In the NHEJ reaction, the
MRN complex processes the free DNA ends, followed by DNA end binding by Ku
(Ku70-Ku80 complex). Then, Ku binds the DNA-dependent protein kinase catalytic
subunit (DNA-PKcs), forming an enzyme complex called DNA-PK. DNA-PK activates a
complex of XRCC4 and ligase IV, which link and ligate the broken DNA ends together
(reviewed in Weterings, Chen 2008). NHEJ is error-prone, as deletions occur due to the
degradation of the DNA ends in the search for microhomology before the two DNA ends
can be joined. An exception, however, are the cases where the two DNA ends have
complementary overhangs, such as when the DNA break is induced by nucleases in V(J)D
recombination or class-switch recombination, both important processes in the production
of antibodies, and both of which use the NHEJ machinery for DNA strand reattachment
(Lieber et al. 2004).
Translesion synthesis
Translesion synthesis (TS) is an error-prone mechanism, which uses specific TS
polymerases (e.g. pol  ,  pol  ,  pol   and  Rev1)  to  replicate  the  DNA strand  past  lesions
which block the progress of the replicating high-fidelity polymerases  and . This activity
is called lesion bypass. TS polymerases insert bases opposite to the damaged nucleotides
with low fidelity, resulting in frequent mis-insertions, which promote mutagenesis
(McCulloch, Kunkel 2008). Although it introduces replication errors in DNA, the TS
pathway can circumvent more severe conditions, such as double-strand breaks, which
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occur  when  replication  forks  collapse.  In  addition  to  lesion  bypass,  TS  polymerases  are
also active in some DNA repair pathways, such as HR, NER and BER (Kawamoto et al.
2005, Ogi, Lehmann 2006, Prasad et al. 2003), and defects in them have been connected
to cancer susceptibility in mice and man (Dumstorf et al. 2006, Lin et al. 2006, Broughton
et al. 2002).
DNA damage response pathway
In ideal cases, when DNA damage is detected, the damage is repaired fast and with high
fidelity to ensure DNA integrity and continuation of the cell cycle. However, in some
cases the process is slow or not possible, and the cell cycle has to be arrested until DNA
repair is complete. This activity is mediated by specific signalling cascades, which
activate the DNA damage response (DDR) pathway. DDR co-operates with DNA repair
and contributes to enhanced repair and the activation of cell cycle checkpoints.
Alternatively, if the damage persists, DDR directs the affected cell to apoptosis or
senescence (Rouse, Jackson 2002).
DDR  sensors,  which  detect  damage  to  DNA,  are  probably  the  proteins  of  DNA
repair pathways which recognise and bind to their specific target lesions. If the problem
persists, DDR is activated. The central proteins mediating the DDR signals are the
phosphatidyl-inositol 3-kinase (PI3K) -like protein kinases Ataxia-Telangiectasia mutated
(ATM) and ATM and Rad3-related (ATR). ATM is activated mainly in response to DSBs,
whereas ATR has a more diverse variety of activators (Abraham 2001). Activation of
these kinases leads to the phosphorylation of their downstream targets, which include the
signal transducers checkpoint kinase 2 (CHK2) and CHK1, and the common DNA
damage response signalling protein p53. These phosphorylation cascades lead to e.g.
H2AX histone phosphorylation and the accumulation of repair factors such as the
MRE11-RAD50-NBS1 (MRN) complex at the site of the lesion, cell cycle checkpoint
activation, increased transcription or posttranslational modification of DNA repair factors,
and eventually, if the problem persists, cell death (Rouse, Jackson 2002). Germline
alterations in the DDR pathway genes lead to cancer syndromes, such as ataxia
telangiectasia (the mutated gene is ATM) (Savitsky et al. 1995), Nijmegen breakage
syndrome (NBS1) (Matsuura et al. 1998), and Li-Fraumeni syndrome (p53) (Malkin et al.
1990, Srivastava et al. 1990). Moreover, p53 is sporadically inactivated in about 50% of
cancers, emphasizing the extreme importance of the DDR pathway (Soussi et al. 2006).
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MISMATCH REPAIR
In  the  course  of  DNA  replication,  it  is  estimated  that  despite  efficient  proofreading,  the
replicating polymerase makes an insertion mistake every 106-107 bases it incorporates into
nascent DNA (Kolodner, Marsischky 1999). Mismatch repair (MMR) is the DNA repair
machinery responsible for correcting these errors. The most common mispair is G•T,
which causes only a slight DNA strand distortion (Hunter et al. 1987), and therefore is the
most likely mispair to be ignored by the polymerase’s proofreading activity. Another
common type of error arises during the replication of repetitive sequences such as
common adenine mononucleotide repeats or CA-dinucleotide repeats, so-called
microsatellites. During the replication of these sequences, the two DNA strands
occasionally detach and renature, giving rise to extrahelical unpaired nucleotides
(insertion-deletion loops, IDLs) (Kunkel 1993). MMR screens along the postreplicative
DNA and corrects the mismatches and IDLs, thereby reducing the spontaneous mutation
rate by a further two to three orders of magnitude (Modrich, Lahue 1996).
In addition to their best characterised function in monitoring postreplicative DNA,
MMR  proteins  are  also  involved  in  many  other  cellular  processes,  which  are  briefly
described  here.  For  example,  the  MMR  system  recognises  a  variety  of  DNA  lesions
caused by e.g. alkylating agents, 6-thioguanine, and cisplatin, and mediates cell cycle
checkpoint activation and apoptosis (Karran 2001). MMR also plays a role in somatic
hypermutation, which occurs in B lymphocytes after antigen stimulation. There, MutS  is
believed to recognise the G•U mispairs caused by activation-induced cytidine deaminase
(AID), mediate the excision of the U containing strand, and recruit error-prone translesion
polymerases to fill the single-stranded gap (Peled et al. 2008). The MMR activity in
somatic hypermutation leads to mutations primarily in A•T base pairs, whereas base
excision  repair  glycosylases  and  replication  of  G•U  mispairs  leads  to  mutations  in  G•C
base pairs (Rada et al. 1998). Another function of MMR proteins is to suppress
recombination of similar but not identical, homeologous sequences (Surtees, Argueso &
Alani 2004). On the other hand, large triplet repeat expansions which are associated with
many neurodegenerative diseases, such as myotonic dystrophy and Huntington’s disease,
seem to be dependent on active MMR (Manley et al. 1999, Savouret et al. 2004).
Despite the variety of activities played by MMR, the main function and focus of
this work is the repair of DNA mispairs arising during DNA replication. The fundamental
difference between MMR and the DNA damage repair pathways dealing with chemically
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altered DNA is that in MMR, no malformed DNA bases are involved, thus creating the
dilemma of  which  strand  to  degrade  and  which  one  to  use  as  a  template.  Therefore,  the
repair has to be directed to the newly synthesised strand, which by default contains the
incorrect nucleotide.
MMR in Escherichia coli
MMR was first described in prokaryotes and the reaction was reconstituted in vitro
already in 1989 (Lahue, Au & Modrich 1989). Mismatch recognition in E. coli is
performed by a homodimer of two MutS-proteins. Mismatch-bound MutS complex is then
bound  by  another  protein,  the  homodimeric  MutL.  The  MutS-MutL-DNA  complex
activates MutH which functions as a latent endonuclease and the strand discrimination
sensor. The strand discrimination is based on the transient absence of methylation at the
GATC-sites in the nascent strand, where deoxyadenine (DAM) methylase adds methyl
groups about 2 minutes after DNA synthesis. MutH incises the DNA in the vicinity of the
mismatch by the closest unmethylated GATC-site (Grilley, Griffith & Modrich 1993).
DNA is unwound by DNA helicase II (MutU), allowing exonucleases, such as ExoI, RecJ,
ExoVII or ExoX to excise the incorrect strand past the mismatch. The resulting gap is
filled by DNA polymerase III and sealed by DNA ligase (Burdett et al. 2001, Modrich,
Lahue 1996). Additional proteins required for the reaction include single-strand binding
protein (SSB), which coats the ssDNA gap resulting from exonuclease activity; -clamp
protein, which possibly recruits MutS to mismatches and is required for the processivity of
DNA polymerase III; and  Complex, which loads the -clamp onto DNA (Kunkel, Erie
2005). The outline of the E. coli MMR is depicted in Figure 1.
24
Figure 1. Mismatch repair in E.coli. (1) A G-T mispair has escaped the replicative polymerase’s
proofreading activity. (2) A dimer of MutS binds to the mismatch and attracts dimeric MutL to the
site, and the endonuclease MutH is activated. MutH incises the newly synthesised strand in the
vicinity of the closest unmethylated GATC site. (3) Exonucleases degrade the nascent strand until
the mismatched DNA has been removed. (4). The resulting single-stranded gap is bound by single-
stranded protein (SSB). (5) DNA polymerase III fills the gap using the intact strand as a template.
(6) The mismatch has been corrected, sealed by ligase, and the new strand methylated by DAM
methylase.
MMR in eukaryotes
In eukaryotes, the MMR reaction and involved proteins are highly similar to their
prokaryotic counterparts, albeit with some differences. A great deal of work has been done
in yeast, contributing significantly to the knowledge of eukaryotic MMR we have today
(Reviewed in Fishel, Kolodner 1995). In this work, the main focus is on the human
system, but the yeast (Saccharomyces cerevisiae) MutS and MutL homologues are shortly
introduced.
In humans, there are altogether 5 MutS homologues, of which MutS Homologues
MSH2, MSH3 and MSH6 have been associated with MMR (Drummond et al. 1995,
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The corresponding protein homologues are also found in yeast. Furthermore, a sixth MutS
homologue, Msh1, not found in mammals, is reported to function in yeast mitochondrial
MMR (Reenan, Kolodner 1992). In contrast to the prokaryotic proteins, which act as
homodimers, MutS and MutL homologues function in eukaryotes as heterodimers. The
mispair recognition is done by a MutS homologue heterodimer, but the exact dimer
composition depends on the type of lesion. Base-base mismatches and small (<2 bp) IDLs
are recognised by a complex of MSH2 and MSH6 (MutS ), whereas an MSH2-MSH3
(MutS ) complex recognises only IDLs (Acharya et al. 1996, Palombo et al. 1996). Thus,
MSH6 and MSH3 play partially redundant roles in MMR.
The human MutL Homologues are MLH1, MLH3, PMS1 (Post-Meiotic
Segregation 1) and PMS2. In yeast, the closest homologue of human PMS2 is Pms1,
whereas yeast Mlh2 corresponds to human PMS1 (Wang, Kleckner & Hunter 1999). In
human MMR, the heterodimer of MLH1 and PMS2 (MutL ) is the most important MutL
complex, but also the MLH1-MLH3 (MutL ) complex is able to repair base-base
mismatches in vitro, and is suggested to act as a backup for MutL  (Cannavo et al. 2005,
Korhonen et al. 2007). In yeast, the main MutL homolog is Mlh1-Pms1, and the Mlh1-
Mlh3 complex has been reported to participate in the repair of >3 bp insertion-deletion
loops (Flores-Rozas, Kolodner 1998). The roles of human MLH1-PMS1 -complex
(MutL ) (Raschle et al. 1999) and yeast Mlh2 (Wang, Kleckner & Hunter 1999) are
uncertain. The eukaryotic MutS and MutL are presented in Table 2.
Table 2. E.coli, yeast, and human MutS and MutL homologues.
E. coli Yeast Human Function in MMR
MutS Msh1 - Mitochondrial MMR
Msh2 MSH2 Mismatch and IDL recognition
Msh3 MSH3 IDL recognition
Msh4 MSH4 (Meiotic recombination)*
Msh5 MSH5 (Meiotic recombination)*
Msh6 MSH6 Mismatch and small IDL recognition
MutL Mlh1 MLH1 MMR assembly
Mlh3 MLH3 MMR assembly and endonuclease
(backup?)
Pms1 PMS2 MMR assembly and endonuclease
Mlh2 PMS1 ?
*These proteins do not have a function in DNA repair
Although several eukaryotic MutS and MutL homologues have been identified,
homologues for the endonuclease MutH have not been found. The excision of the
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incorrect strand in eukaryotes has been suggested to begin from the free DNA end
associated  with  the  progression  of  the  replication  fork,  either  at  the  3’  or  5’  end  of  the
Okazaki fragment in the lagging strand, or the 3’ end of the leading strand (Modrich,
Lahue 1996). Given the lack of GATC methylation in eukaryotic DNA, the strand
discontinuity could also account for the strand discrimination signal. Alternatively, strand
discrimination might be directed through the interaction of MMR proteins with the
replisome-associated proliferating cell nuclear antigen (PCNA) (Bowers et al. 2001, Umar
et al. 1996), which is the processivity factor for replicative DNA polymerases. Recently,
however, the significant finding that MutL  possesses a cryptic endonuclease activity was
reported (Kadyrov et al. 2006). This activated endonuclease introduces several incisions
primarily on the 5’ side of the mismatch in the MMR reaction. The activity is disturbed by
inactivating mutagenesis in the identified endonuclease sequence motif in the C-terminus
of the PMS2 subunit. This endonuclease (DQHA(X)(2)E(X)(4)E) sequence motif is also
present in the prokaryotic endonuclease MutH. Human MLH3, but not PMS1, contains the
motif, supporting the interpretation that MutL , but not MutL , plays a role in MMR.
Eukaryotic MMR has also been reconstituted in vitro (Constantin et al. 2005,
Zhang et al. 2005). The MMR substrate mimicking the replication error was a double-
stranded DNA plasmid with a mismatch and a single-strand nick either 3’ or 5’ of the
mismatch. Such breaks direct the MMR reaction to the correct DNA strand in human cell
extracts (Holmes, Clark & Modrich 1990, Thomas, Roberts & Kunkel 1991b). The factors
required for the 5’ reaction (nick situated 5’ of the mismatch) were MutS ; PCNA;
replication factor C (RFC), which loads PCNA on the DNA; Exonuclease I (EXOI), which
excises the newly synthesised DNA strand; single-strand binding protein RPA, which
binds to the ssDNA gap resulting from the ExoI activity; and polymerase , which fills the
gap using the intact strand as a template. Surprisingly, only the 3’ reaction required MutL
(Constantin et al. 2005). Another study reported that also the protein HMGB1 was needed
for the reaction (Zhang et al. 2005).
The  lack  of  MutL  requirement  in  5’-directed  MMR  reconstitution  is  as  yet  not
understood, as lack of MLH1 is the classical cause for MMR deficiency both in vitro and
in vivo (Li, Modrich 1995, Lindblom et al. 1993),  and  MutL  is  believed  to  be  an
indispensible molecular matchmaker in the MMR reaction (Jiricny, Nyström-Lahti 2000).
The recent finding that MutL  is an endonuclease which provides the 5’ break for excision
initiation for 5’-3’ exonuclease ExoI (Kadyrov et al. 2006) partially explains the
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dispensability of MutL  in the MMR reconstitution with the 5’-nicked heteroduplex. Why
the MMR of 5’-nicked substrates does not occur in MLH1-deficient cell extracts (e.g.
Nyström-Lahti et al. 2002, Raevaara et al. 2005) is yet to be clarified. The proteins
required for MMR reconstitution in prokaryotes and eukaryotes are listed in Table 3. The
overview of the current model of eukaryotic MMR is depicted in Figure 2.
Table 3. E.coli and Human MMR proteins.
E. coli Human Function




DNA helicase II (MutU) - DNA helicase
ExoI, RecJ, ExoVII ExoI (and others?) Exonuclease
SSB RPA (and HMGB1) Single-strand gap protection
DNA pol III DNA pol Polymerase
-clamp PCNA Polymerase processivity factor
 Complex RFC Processivity factor loader
MutL MutL , MutL
Figure 2. A model for eukaryotic MMR. (1) Strand discontinuity, either 3’ or 5’ from the
mismatch, serves as the strand discrimination signal in the MMR reaction. How the strand
discrimination  signal  is  communicated  to  the  site  of  nicking  is  unclear.   (2)  MutS  binds  to  the
mismatch and recruits MutL  to the site. (3) MutS  (possibly bound to MutL ) leaves the site of
mismatch in search of strand discontinuity. MutL  makes several incisions in the repairable strand
in the vicinity of the mismatch. (4) RPA covers the resulting ssDNA. (5) DNA polymerase  fills











































MutL DNA Pol RPA
MutS EXOI                      DNA ligase 1
28
Role of MutS  in MMR
When screening postreplicative DNA, MutS  is suggested to be physically attached to the
replication machinery by an MSH6-mediated contact to polymerase processivity factor
PCNA (Kleczkowska et al. 2001). Upon encountering a misintegrated base or an IDL,
MutS  binds to the mismatch. It then recruits MutL  to the site, and releases the mismatch
by sliding from the site along the DNA in order to allow the subsequent repair process to
take place (Blackwell et al. 1998, Gradia et al. 1999). MutS  changes conformational
states from general DNA sliding to mismatch binding and downstream signalling mode by
alternating the binding of adenine nucleotides in its two subunits, both of which possess an
ATP-binding and hydrolysis domain in their carboxy terminus (Warren et al. 2007). As
these ATP / ADP switches control the DNA binding activities of the heterodimer, the
nucleotide binding and hydrolysis activities of MutS  are vital, and mutations in the
ATPase domains of MSH2 and MSH6 have been shown to inactivate functional MMR
(Dufner et al. 2000, Iaccarino et al. 1998). To date, the exact mode of MutS  translocation
along DNA remains uncertain. The two favoured models are known as the “sliding clamp”
model (Gradia, Acharya & Fishel 1997a) and the “active translocation” model (Blackwell
et al. 1998).  These  models  differ  in  terms  of  the  energy  requirement  for  the  movement
along DNA – the former suggests that several MutS  clamps diffuse stochastically in both
directions from the mismatch until they find the strand discontinuity signal, and the latter
proposes that the translocation is ATP hydrolysis-driven. However, both models agree that
MutS  binds mismatches in an ADP-bound state, and that switching of ADP to ATP
mediates a conformational change in the molecule, allowing movement along DNA.
Whether the whole MutS -MutL  ternary complex, which forms upon the mismatch, or
MutS  alone actually slides along the DNA remains unknown.
Structure of MutS
While crystal structures of prokaryotic MutS dimers have been available since 2000
(Lamers et al. 2000b, Obmolova et al. 2000), the human MutS  structure was solved only
recently (Warren et al. 2007). As already demonstrated by the prokaryotic structures, the
two MutS subunits are organised asymmetrically. The human structure confirmed the
previous observations made by mutagenesis experiments that MSH6 is the mismatch
binding monomer of MutS  (Dufner et al. 2000). According to both the prokaryotic MutS
and human MutS  crystal structures, both subunits of the complex are divided into five
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functional subunits: a DNA-binding domain (domain 1), a connector domain (domain 2), a
lever domain (domain 3), a clamp domain (domain 4) and an ATPase domain (domain 5).
Furthermore, the extreme C-terminus in both monomers contains a helix-turn-helix-motif,
which stabilizes the ATPase domains of the MutS  subunits (Lamers et al. 2000a,




Figure 3. The crystal structure of human MutS  on mismatched DNA. A. The MSH6 subunit
of the MSH2-MSH6 heterodimer is displayed on the left, and coloured with light brown. The
MSH2 subunit is on the right and its separate functional domains are coloured differentially.
Yellow: domain I, DNA binding domain; dark blue: domain II, connector domain; green: domain
III, lever domain; grey: domain IV, clamp domain; light blue: domain V, ATPase domain. B. The
same structure rotated 90°. The crystal structure represents MutS  bound to a G•T mismatch, and
both monomers carry ADP. According to Warren et al. 2007.
The DNA-binding domain of MSH2 makes an unspecific DNA contact in the
vicinity of the mismatch, while MSH6 is responsible for the actual binding to the
mismatch. The connector domain connects the DNA-binding subunit to the rest of the
MutS  heterodimer, and is responsible for the intramolecular interactions and allosteric
signalling between different protein domains. The lever domain is a large domain which
connects the ATP-binding subunit to the clamp domain, which makes unspecific DNA
contacts. It is believed to mediate signals between the ATP- and DNA binding parts of the
protein and to communicate the structural transformation messages. The ATP-binding /
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hydrolysis subunit modulates the conformation of the protein dimer by binding either no
nucleotide, ADP or ATP. As the ATP-binding sites can be occupied by different ligands,
the  two  sites  can  exist  in  several  different  combinations.  Because  of  this,  it  has  been
difficult to exclusively determine the nucleotide-binding states of MSH2 and MSH6 in
different stages of the MMR reaction (Gradia, Acharya & Fishel 2000, Warren et al.
2007).
Human MutS  has been crystallised bound to four different DNA lesions (Warren
et al. 2007). The G•T mismatch and the unpaired T nucleotide represent replication errors,
the  classical  MMR  substrates.  As  mentioned  above,  MutS  is  known  to  be  involved  in
other cellular pathways, for example somatic hypermutation and the response to alkylating
damage. A yeast study proposed that the conformation of MutS , bound to its substrate, is
determined by the pathway it is employed in (Drotschmann et al. 2004). To address this
issue in humans, human MutS  complex was also crystallised bound to two other
structures: a G•U mispair, reflecting somatic hypermutation, and an O-6-Methyl-G•T, a
lesion resulting from alkylating damage. All four substrates were bound similarly,
indicating that although MutS  plays a role in several cellular processes, the different
signalling does not represent differences in the substrate binding. Instead, varying
downstream factors are more likely to mediate the variety of responses (Warren et al.
2007).
Defective MMR
As in  other  DNA repair  pathways,  also  defective  MMR leads  to  genetic  instability.  The
main role of MMR is to correct postreplicative errors in DNA, and MMR deficiency gives
rise to point mutations and, in particular, variety in the length of short repetitive
sequences, microsatellites. This variety results from unrepaired IDLs, and is called
microsatellite-instability (MSI). Due to the accumulation of MSI and other replication
errors in the genome, MMR deficiency eventually leads to cancer. MMR defects are
frequently found in sporadic tumours, and inherited MMR deficiency leads to hereditary
nonpolyposis colorectal cancer (HNPCC), also called Lynch syndrome (Lynch, de la
Chapelle 1999a).
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HEREDITARY NONPOLYPOSIS COLORECTAL CANCER
HNPCC is a relatively common hereditary cancer syndrome, accounting for
approximately 2-3% of all colorectal cancers (CRCs) (Lynch, de la Chapelle 2003,
Salovaara et al. 2000). The susceptibility to cancer is inherited in an autosomal dominant
manner. HNPCC was first reported already in 1913, when Aldred S. Warthin described a
family with a hereditary occurrence of gastric cancer (Lynch, Krush 1971). In the 1960s
and 1970s, attention was redrawn to the syndrome by Henry T. Lynch. He characterised
several hereditary cancer families suffering from familial colorectal and some extracolonic
cancers, mainly endometrial tumours (Lynch, Smyrk & Lynch 1998). Thus, the existence
of a familial CRC syndrome was characterised already long before its genetic basis was
revealed. The syndrome was called hereditary nonpolyposis colorectal cancer to
differentiate it from other known hereditary CRC syndromes, such as familial
adenomatous polyposis (FAP), juvenile polyposis and Peutz-Jeghers syndrome, all of
which are characterised by the occurrence of numerous polyps in the large intestine (for a
recent review on colorectal polyposis syndromes,  see e.g. Jass 2008).
Genetics of HNPCC
The connection between germline defects in MMR genes and HNPCC was established
when the first susceptibility genes MSH2 (Leach et al. 1993, Peltomäki et al. 1993b) and
MLH1 (Lindblom et al. 1993, Papadopoulos et al. 1994) were found and mutations in
them were shown to segregate with cancer in HNPCC families. Furthermore, MSI,
resulting from defective repair of IDLs, was found to be the hallmark of HNPCC tumours
(Aaltonen et al. 1993). To date, inherited mutations in MLH1, MSH2, MSH6 and PMS2
have been shown to predispose to HNPCC, whereas the role of MLH3 is elusive and
MSH3 and PMS1 most likely do not participate in cancer predisposition.
To date, over 1500 different variants have been identified in the four HNPCC
genes. By February 2007, 659 unique variants in MLH1 (44% of all identified MMR gene
variants), 595 in MSH2 (39%), 216 in MSH6 (14%) and 45 in PMS2 (3%) had been
published (Woods et al. 2007). The most typical alterations found in MMR genes are
missense mutations and insertions / deletions. Splice site, silent and nonsense variations
are somewhat less frequent. Mutations are not clustered in hot spots. Exon 17 in MLH1
and exon 11 in MSH2 are the most frequently mutated, if the number of variations is
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correlated with the length of the exon (Woods et al. 2007). Founder mutations, affecting
several families in a typical geographical area, are rare. A common splice-site mutation in
MSH2 intron 5 has been found in several countries, for example in the US and England
(Froggatt et al. 1999), and the deletion of exons 1 to 6 is a founder mutation in the US
(Clendenning et al. 2008). In Finland, a splice-site mutation in MLH1 exon 6 and a
deletion of MLH1 exon 16 account for the majority of HNPCC mutations (Nyström-Lahti
et al. 1995). The MSH2 missense mutation A636P is present in about one-third of
HNPCC cases in Ashkenazi Jews (Guillem et al. 2003, Guillem et al. 2004).
Due to the large amount of identified genetic variations in MMR genes, attempts
have been made to collect the information into internet databases to distribute it to
HNPCC researchers and clinicians. The first HNPCC mutation database was established
and maintained by the International Society for Gastrointestinal Hereditary Tumors
(InSiGHT) (www.insight-group.org). This database relies on entries of original data from
investigators and therefore only includes information provided by the depositor. Recently,
a significant contribution to HNPCC mutation compilation has been made by Michael
Woods and colleagues, who have assembled all published MMR mutations in one
database (Woods et al. 2007, www.med.mun.ca/MMRvariants).
According to the two-hit hypothesis, HNPCC is inherited dominantly but, as in the
case of many hereditary cancers, the tumorigenesis requires the inactivation of the second
allele (Knudson 1996). This second hit can occur for example through promoter
hypermethylation, loss of heterozygosity, or gene conversion (Yuen et al. 2002, Zhang et
al. 2006). Thus, the first allele being absent in the germline, the second hit inactivates
MMR. This leads to the failed correction of IDLs and therefore to MSI. MSI, then, affects
several genes by altering their reading frame. Among the most often reported MSI target
genes are TGFßRII, BAX, and IGFIIR, which all contain mononucleotide repeats in the
coding sequence (Markowitz et al. 1995, Rampino et al. 1997, Souza et al. 1996), and act
as suppressors of cellular growth (TGFßRII, and IGFIIR) or as proapoptotic proteins
(BAX).  Also  the  MMR  genes MSH3 and MSH6, and a number of others, have been
described as MSI target genes (Duval, Hamelin 2002, Malkhosyan et al. 1996).
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Clinical characteristics of HNPCC patients
HNPCC-related CRCs have some typical characteristics, although none of those allow
reliable discrimination from sporadic CRC. The average age of HNPCC onset is about 45
years, in contrast to sporadic cancers, which appear some 20 years later (Lynch, de la
Chapelle 1999b, Peltomäki, Gao & Mecklin 2001). In HNPCC, tumours are situated
mainly in the proximal colon, and multiple synchronous and metachronous tumours are
common. HNPCC patients have better prognosis than sporadic CRC patients, and the
tumours have typical histological features, such as tumour-infiltrating lymphocytes and
mucinous differentiation (Umar et al. 2004). HNPCC is also characterised by the frequent
occurrence of various extracolonic tumours, mainly in the endometrium, small intestine,
hepatobiliary tract, stomach and skin (Muir-Torre syndrome, see below). The penetrance
of the cancer phenotype in MSH2 or MLH1 mutation carriers has been estimated to be
close to 100%, whereas MSH6 mutation carriers have slightly reduced and PMS2 mutation
carriers significantly lower penetrance (Peltomäki 2005). The risk of CRC in MMR
mutation carriers is estimated to be around 80% by the age of 70 years, with females
having a somewhat lower risk than males. Endometrial cancer is even more common than
CRC in females, showing about 50 – 60% penetrance (Aarnio et al. 1999a, Vasen et al.
1996). The life-time risk of other extracolonic cancers is estimated to be between 2 and
10% (Watson, Lynch 2001).
Several clinical criteria have been introduced to unify the international practice of
HNPCC  diagnostics  and  to  identity  the  HNPCC  families  from  the  frequent  sporadic
CRCs. The first diagnostic criteria, the Amsterdam criteria (AC), were created 1991
(Vasen et  al. 1991). AC are based on the young age of onset and familial occurrence of
CRC. These criteria were later modified to include the extracolonic tumours of the
HNPCC tumour spectrum in the diagnostic guidelines (ACII), (Vasen et al. 1999). The
Amsterdam criteria are specific and only rarely identify false positive cases, but they are
not  sensitive  and  many  HNPCC  families  will  be  missed  if  these  are  used  as  the  single
criterion. Therefore, the Bethesda guidelines were established to identify the HNPCC
families who, due to e.g. small family size or insufficient information, were not found
with AC (Rodriguez-Bigas et al. 1997). These criteria made use of the MSI phenotype
associated with HNPCC tumours. Also the Bethesda criteria have been later modified
(Umar et al. 2004). Both revised criteria are detailed in Table 4.
34
Table 4. The diagnostic criteria for HNPCC.
Amsterdam Criteria II (All of following
conditions fulfilled)
Revised Bethesda guidelines (Any of the following
conditions fulfilled)
•At least three relatives with HNPCC-associated •CRC diagnosed in a patient before age 50
cancer (in colorectum, endometrium, small •Presence of synchronous, metachronous CRC or
bowel, ureter, renal pelvis) other HNPCC associated tumours, regardless of age
•One should be a first degree relative of the •CRC with the MSI-high histology* diagnosed in a
other two patient before age 60
•At least two affected generations •CRC diagnosed in one or more first-degree
•At least one member diagnosed before age 50  relatives with an HNPCC-associated tumour, with
•FAP should be excluded one of the tumours diagnosed before age 50
•Tumours should be verified by pathological •CRC diagnosed in two or more first- or second
 examination degree relatives, with HNPCC-associated tumours,
regardless of age
*For definition of MSI status, see text below.
Microsatellite-instability and immunohistochemistry in HNPCC diagnostics
Management of the cancer families and the applied tumour therapy differs between
HNPCC and sporadic CRCs. Therefore, phenotypic features helping the diagnostics of
HNPCC are very important to indicate the requirement for mutation analysis. Phenotypic
characteristics  of  HNPCC  tumours  include  MSI  and  loss  of  expression  of  an  MMR
protein, reflecting the underlying MMR defect.
MSI analysis is informative for establishing whether the tumour is MMR-deficient
or  not,  but  is  not  specific  to  HNPCC,  due  to  the  frequent  somatic  inactivation  of  the
MLH1 promoter in sporadic CRCs (Thibodeau et al. 1998). However, MSI analysis is
often used as a rough screening method for MMR defect. In MSI testing, a general panel
of 5 microsatellite markers are used. If two or more of those are unstable, the tumour is
classified MSI-high (MSI-H) (Boland et al. 1998).
Immunohistochemical (IHC) assessment of the expression of MMR proteins in
tumours is another widely used method for detecting MMR deficiency. Lack of expression
gives a good indication of the MMR factor behind the MSI phenotype. This holds
especially true for MSH2 (Mangold et al. 2005), whereas lack of MLH1 expression is
often due to promoter hypermethylation. On the other hand, the expression of a protein
does not always indicate that it is functional (Mangold et al. 2005, Raevaara et al. 2005).
It is also to be noted that MMR proteins function as heterodimers, and some monomers
are not stable without their partners (Chang et al. 2000). Thus, if MSH2 is absent, also
MSH6 staining is negative, due to the instability of MSH6 without MSH2. The same is
true for PMS2: without MLH1, PMS2 degrades. Solid knowledge of the expression
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profiles of all four genes gives a good idea where to look for the germline mutation
(Hampel et al. 2005).
Muir-Torre syndrome
Muir-Torre  syndrome  (MTS)  is  a  rare  subtype  of  HNPCC.  A  recent  report  showed  that
about 9% of individuals with HNPCC also exhibit MTS (South et al. 2008). In addition to
tumours of the HNPCC spectrum, the patients also display skin tumours, predominantly
sebaceous gland tumours or keratoacanthomas (Cohen et al. 1995, Schwartz et al. 1989).
Both skin and visceral tumours in MTS display high MSI (Kruse, Ruzicka 2004a),
reflecting the underlying MMR defect. Potentially, a skin tumour with a diagnosed
germline MMR defect could be of strong clinical importance, allowing the diagnosis of
MTS already before the visceral cancer manifestates. This would greatly contribute to
early surveillance and cancer prevention in the mutation carrier.
By 2006, a total of 41 MMR gene mutations linked to MTS had been reported. 38
of these mutations were situated in MSH2 and only three in MLH1, suggesting a strong
bias of MTS syndrome associating with only one MMR gene, MSH2 (Bapat et al. 1999,
Kruse, Ruzicka 2004b, Mangold et al. 2004, Ponti et al. 2005). This is in contrast to
HNPCC, where MLH1 is the most frequently mutated predisposing gene (Peltomäki et al.
2005). In addition, only three of the MTS-linked mutations were of the missense type
(7%), in contrast to the fact that 22% of all reported MMR gene variations and 17% of
MSH2 variations are missense mutations (www.med.mun.ca/MMRvariants). Some recent
systematic studies suggest, however, that MLH1 mutations could play a more frequent role
in MTS than previously thought (Ponti et al. 2006, South et al. 2008), and that also MSH6
mutations are involved (Mangold et al. 2007, Murphy et al. 2008).
NONTRUNCATING MUTATIONS IN HNPCC
Frequency of nontruncating mutations in MMR genes
A major problem in the diagnosis and management of HNPCC is the frequent occurrence
of nontruncating mutations. As in all genes, a point mutation, which changes one amino
acid in the polypeptide, may either have a harmful (or beneficial) effect on protein
function or not affect the function at all. Thus, when encountering a nontruncating
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mutation in an MMR gene in a putative HNPCC family, the interpretation can be very
difficult, especially if the co-segregation of the mutation and cancer phenotype cannot be
confirmed. In MMR genes, nontruncating variations are the most common type of
reported mutations (Woods et al. 2007), with missense mutations alone accounting for
24% of MLH1, 17% of MSH2, and 27% of unique MSH6 variations.  Of  the  reported
PMS2 mutations, missense variants account for nearly 50%
(http://www.med.mun.ca/MMRvariants). The pathogenicity of a sequence variation is
classically determined based on the conservation status and biochemical significance of
the amino acid change, segregation of the mutation with the cancer phenotype, and MSI
and IHC status of the tumours of the mutation carriers (Barnetson et al. 2007, Genuardi et
al. 1999). However, the clinical phenotype of a nontruncating mutation may vary within
different  families,  and  segregation  data  is  not  always  available.  Therefore,  functional
assays have been developed to clarify the activity of nontruncating MMR gene mutations.
The following chapters summarize the techniques used in the functional characterisation
of MMR gene defects.
Functional analysis of nontruncating MMR gene variants
Functional assays aim to investigate how a nontruncating mutation affects the biological
and biochemical behaviour of a protein variant as compared to the wild type (WT).
Recently, data concerning the published functional assays on MMR genes has been
collected (Ou et al. 2007) and listed in a database (www.mmrmissense.net). With
functional testing, one can show that the observed genetic variation really reflects the
observed phenotype. In the case of MMR proteins, the functional assays can be divided in
two major classes: the ones which measure the success of an MMR reaction, and the ones
which monitor one specific function of the MMR protein in question. The former ones can
be conducted in vivo in yeast assays, or in vitro using mammalian cell extracts. The latter
ones measure activities such as heterodimer subunit interaction, DNA binding, or
subcellular localization. The two types of MMR assays complement each other, as the
success of an MMR reaction gives information about the functionality of a given variant,
but does not elucidate the reasons behind the putative pathogenicity. Recently, also several
computational methods have been developed to assess the tolerability of MMR gene
amino acid substitutions.
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In vivo MMR assays in yeast
Yeast is an optimal model organism to assay MMR functions in vivo due  to  the
conservation between human and yeast MMR systems and the facility of yeast-based
techniques. Two main approaches are in use. Mutations corresponding to patient-derived
MMR gene mutations can be constructed in homologous positions in the yeast genome
and the mutation rate caused by the mutant protein can be determined (Shcherbakova,
Kunkel 1999, Drotschmann et al. 1999, Gammie et al. (2007). Alternatively, the fact, that
human MMR proteins are able to bind yeast MMR factors and block the intrinsic MMR
activity in yeast, has been exploited. WT and functionally intact mutations introduced to a
WT yeast cause a mutator phenotype, whereas non-functional human MMR proteins fail
to  do  so  (Clark et al. 1999, Shimodaira et al. 1998, Clark et al. 1999, Takahashi et al.
2007). The two methods can be used to complement each other (Drotschmann, Clark &
Kunkel 1999).
Although important tools in assessment of the activity of putative HNPCC-related
MMR mutations, yeast MMR assays harbour the problem that they always rely on the
homology between human and yeast proteins, allowing only the conserved amino acids to
be tested. However, Ellison et al. (Ellison, Lofing & Bitter 2001) developed an assay
where they used yeast-human MLH1 hybrid proteins in a yeast context.
In vitro MMR assays in cell lysates
The homology limitation and cross-species difference problems related to yeast assays can
be overcome by using homologous human in vitro assays. These human systems are not
limited  to  conserved  amino  acids,  and  all  reactions  make  use  of  human  proteins.  These
assays are based on mismatched DNA substrates, which mimick the repairable cellular
DNA. These substrates are incubated with human cell extracts. The detection of successful
MMR is based on the in vitro correction of the mismatch, resulting either in a restriction
site (Lahue, Au & Modrich 1989, Nyström-Lahti et al. 2002) or in a change of reading
frame in the lacZ reporter gene (Thomas, Roberts & Kunkel 1991a).
Assays measuring a specific function of MMR proteins
As both MutS  and MutL  function as dimers, one way to study their functionality is to
assess whether the dimer subunits are able to interact with each other. This has been
addressed by several methods: GST pull-down assays, yeast two-hybrid assays, and co-
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immunoprecipitation assays. (Guerrette et al. 1998, Guerrette, Acharya & Fishel 1999,
Nyström-Lahti et al. 2002, Kondo et al. 2003, Kariola et al. 2004, Raevaara et al. 2005).
DNA-binding experiments (bandshift assays or electrophoretic mobility shift assays) are
based on the in vitro binding of purified MutS  proteins to labelled heteroduplex
oligonucleotides. DNA-binding experiments have revealed defective binding to
heteroduplex oligomers with mutated human and yeast MutS  (Clark et al. 1999,
Drotschmann, Clark & Kunkel 1999, Heinen et al. 2002). Despite of being functional in
an in vitro MMR assay, it is possible that in vivo the mutated protein is never localised to
the nucleus or that its expression levels are reduced. Indeed, both expression and
localization have been studied and found to be defective in context of HNPCC-derived
MMR mutations (Raevaara et al. 2005, Gammie et al. 2007).
In silico prediction algorithms
One way to differentiate between nonpathogenic and pathogenic missense variants is to
use computational algorithms. They are based on comparative sequence or protein
structure analysis. Mostly used are PolyPhen (http://coot.embl.de/PolyPhen) and Sorting
Intolerant From Tolerant (SIFT) (Ng, Henikoff 2003)
(http://blocks.fhcrc.org/sift/SIFT.html). They are based on searching for similar sequences
against a database (e.g. SWISS-PROT/TrEMBL), and aligning the protein sequences from
different species to address the conservation of each amino acid. Alternatively, users can
enter a pre-aligned set of sequences. Probabilities are calculated for each amino acid
substitution and those smaller than a chosen cut-off value are predicted to be deleterious.
The validation of computer-based methods requires the simultaneous use of in silico and
functional analyses of missense variations.
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AIMS OF THE PRESENT STUDY
The main aim of this PhD study was to investigate the pathogenicity of nontruncating
patient-derived mutations in MSH2 to facilitate HNPCC diagnostics in families associated
with these variations. The specific aims were:
1. To assess whether nontruncating mutations in MSH2, found in HNPCC and Muir-Torre
families, cause MMR deficiency (I, II)
2. To clarify the biochemical defect underlying the observed MMR deficiencies (IV)
3. To assess the functionality of two frequently occurring MSH2 variants and to estimate
their connection to cancer predisposition based on in vitro biochemical data and literature
searches (III)
4. To determine whether clinical characteristics of the mutation carriers could be
correlated  with  the  results  of  the  biochemical  analyses,  and  with  the  location  of  the
mutations in the MSH2 polypeptide (II, IV)
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MATERIALS AND METHODS
MSH2 MUTATIONS AND ASSOCIATED FAMILIES (I-IV)
The mutations included in this study consisted of 18 nontruncating MSH2 mutations,
which are discussed throughout this work by referring to the amino acid change in the
corresponding MSH2 residue (GenBank accession number AH003235, version U41206.1
to U41220.1). The studied variants were dispersed across different domains of the MSH2
polypeptide, but were somewhat clustered in the amino (N) -terminal connector domain
and in the adenosine triphosphatase (ATPase) domain at the C –terminus  (Figure 3, p. 29
and Figure 4).
Figure  4.  The  schematic  representation  of  the  studied  mutations  along  the  MSH2
polypeptide. According to Lamers et al. 2000b, Obmolova et al. 2000, Warren et al. 2007.
Fifteen of the mutations were found in putative HNPCC families and came to be
studied through international collaborations, due to the pathogenicity of an identified
nontruncating MSH2 variant being uncertain (T33P, V161D, G162R, G164R, L173P,
L187P, A272V, C333Y, D603N, A636P, C697F, Del 745-746, E749K, A834T and
V923E) (II). Some of these mutations have also been reported in databases by other
research groups (www.insight-group.org). The genetic and clinical characteristics of the
associated families, such as MSI and IHC studies, which were assessed by our
collaborators, are shown in Table 5. The L187P and A272V mutations were found in two,


























































DNA binding domain, aa 1 – 124
Connector domain, aa 125 – 297
Lever domains, aa 300 – 456 and 554-619
Clamp domain, aa 457 – 553
ATPase domain, aa 620 – 855
Helix-turn-helix domain, aa 820 – 934
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HNPCC, mutations L187P and C697F were also associated with families displaying Muir-
Torre syndrome, thus exhibiting concurrent skin and visceral tumours.
Table 5. Genetic and clinical characteristics of the putative HNPCC families associated with
15 nontruncating MSH2 mutations.
 MSH2 MSH6  MLH1
T33P c. 97 A>C 45 / EC 2 / 48  - High  +  +  +
V161D c. 482 T>A 52 / CRC 3 / 53  + High  - ND ND
G162R c. 484 G>A 56 / EC 6 / 52  + High  -  +/-  +
G164R c. 490 G>A 39 / CRC 7 / 39  + ND  - ND  +
L173P c. 518 T>C 36 / CRC 9 / 45  + High*A  - ND  +
L187P c. 560 T>C 41 / CRC 5 / 42  + High  - ND  +
L187P c. 560 T>C 42 / CRC 11 / 48  + High*B  -  -  +
A272V c. 815 C>T 41 / CRC 3 / 40  + Low*C  + ND  +
A272V c. 815 C>T 41 / CRC 1 / 41  - High + + +
C333Y c. 998 G>A 41 / CRC 2 / 41  - ND ND ND ND
D603N c. 1808 G>A 50 / EC 2 / 27  - High  -  -  +
D603N c. 1808 G>A 46 / EC 5 / 55  + Stable  -  -  +
D603N c. 1808 G>A 38 / CRC 1 / 38  - High ND ND ND
A636P c. 1906 G>C 42 / CRC, 44 / EC 2 / 44  + High  -  +/-  +
A636P c. 1907 G>C 43 / CRC 1 / 43  - High - - +
A636P c. 1908 G>C 36 / EC 5 / 49  + High - ND ND
C697F c. 2090 G>T 27 /CRC 5 / 45  + High  - ND  +
C697F c. 2090 G>T 33 / CRC 3 / 38  + High  - ND  +
C697F c. 2090 G>T 40 / EC 3 / 49  + High  -  +  +
Del745-746 c. Del 2235-2240 39 / CRC 4 / 42  + High  -  -  +
E749K c. 2245 G>T 29 / CRC 7 / 29  + High*D  + ND  +/-
A834T c. 2500 G>A 28 / CRC 3 / 39  + High  -  -  +
V923E4 c. 2768 T>A 70 / CRC 6 / 58  + High +/-  -  +












For references, please refer to the Original Article II, from which these data are derived. Each line
corresponds to one family. EC, endometrial cancer; CRC, colorectal cancer; ND; no data. 1Number
of affected patients with HNPCC tumours 2MSI analysis was carried out using the Bethesda panel
(Markers BAT-25, BAT-26, D2S123, D5S346, D17S250 or in some cases D18S69). Two or more
unstable markers were considered as MSI-high. In families marked with an asterisk (*) MSI was
examined with other markers: *A D2S123, D2S136, D6S470, D16S663 (unstable) and HBA1
(stable). *B Bat26 and Mdf15 (unstable). *C TP53-Dint (unstable) D8S254, NM23, D18S35,
D5S346, TP53-Penta, D2S123, D1S2883, D3S1611, D7S501 (stable). *D D2S123, D16S663
(unstable) D5S346, HBA1, D18S35 (stable). 3 MSI and immunohistochemistry were analysed on
the primary tumour from the index patient (for exceptions, see II). 4 The index person carries two
mutations, MSH2 V923E and MSH6 S1188N.
In addition to the 15 mutations listed above, MSH2 N127S and G322D were
studied because of their frequent occurrence both in published CRC families and healthy
individuals and, thus, their contradictory classifications in literature and databases. By
functional analysis, we wanted to clarify their pathogenicity status. The published data on
the clinical characteristics of these variants and their occurrence in the healthy population
is collected in Table 6.
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Table 6. The published clinical and population data of the MSH2 N127S (c.380 A>G) and
MSH2 G322D (c.965 G>A) variants.
N127S HNPCCd + ND ND - -
N127S CRC<50, EC<50 + + ND - MSH2 A328P
N127S CRC ND + ND - -
N127S CRC 40 + + ND - MLH1 frameshift c 1877
N127S CRC<60 - + ND - MSH2 N108N, MLH1 IVS15-5T>C
N127S PC 71, BI C 78 - ND ND ND -
N127S No cancer + ND ND ND -
N127S CRC31 + + - ND MSH2 E422X
N127S CRC34 + + - ND MSH2 E422X
G322D ND ND ND ND + -
G322D CRC + ND ND ND -
G322D CRC36, EC45 ND ND ND + -
G322D CRC19 ND ND ND + G322D homozygote
G322D HNPCC + ND ND + -
G322D CRC40 - ND ND ND -
G322D CRC + ND ND + -
G322D CRC + - ND + -
G322D CRC<50 + + - ND -
G322D ND + ND ND ND MSH2 Q518X
G322D CRC - + ND + -
G322D CRC + + - - MSH2 Q518X
G322D CRC - - + - -
G322D CRC ND ND ND + -
G322D CRC and EC ND + ND ND -
G322D ND ND ND ND + -
G322D CRC39 + + ND ND MLH1 T117M
G322D CRC + / - ND ND - -
G322D EC49 + + + / - + MLH1 D203Ne, MSH2 frameshift














Every row represents one published study. For references, see Original Article III. CRC, colorectal
cancer; EC, endometrial cancer; PC, pancreatic cancer; BI C, biliary tract cancer; ND, no data. a:
The associated cancer type and, when available, age at onset of the index person. b: Microsatellite
instability (MSI) found at least in one tumour of a mutation carrier. c: Immunohistochemical
(IHC) analysis of MSH2 protein expression in tumour tissue. d: Unspecified cancer belonging to
the HNPCC spectrum. e: Somatic mutation.
The mutation G674A (c.2021 G>C) is located in a conserved residue of the MSH2
ATPase domain and was reported to inactivate MMR, but to still be functional in
apoptosis signalling in mouse (Lin et al. 2004). G674A was included in the study because
we wanted to characterise the functional properties of the corresponding human protein.
Another reason was that an HNPCC-associated germline mutation (G674D) has been
reported in the same amino acid residue (Raedle et al. 2001).
The sites of all studied mutations are shown in mapped in the crystal structure of
MutS  in Figure 5.
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Figure 5. Mapping of analysed MSH2 residues in the crystal structure of MutS . The
MSH6 subunit of the MSH2-MSH6 heterodimer is coloured with light brown. The functional
domains of the MSH2 subunit are coloured differentially. Yellow: domain I, DNA binding
domain; dark blue: domain II, connector domain; green: domain III, lever domain; grey: domain
IV, clamp domain;  light  blue:  domain V,  ATPase domain.  DNA is  shown in red and blue in the
lower part of the figure, ADP molecules in red on the upper part. Right: a close-up ribbon structure
of the area containing the studied mutations. According to Warren et al. 2007.
FUNCTIONAL ASSAYS (I-IV)
Protein expression and coimmunoprecipitation (I-IV)
Site-directed mutagenesis and production of baculovirus expression vectors
All used complementary DNAs (cDNAs) were derived from Professor Josef Jiricny’s
laboratory in University of Zürich, Switzerland. WT MSH2 cDNA was cloned into the
pFastBac1 plasmid (Invitrogen) between the vector’s BamHI and XhoI, WT MSH6 cDNA
between its BamHI and XhoI, and WT MSH3 cDNA between its XhoI and XmaI restriction
sites. The MSH6 cDNA construct included a polyhistidine (His6) tag at the N-terminus of
the  MSH6 protein.  The  expression  constructs  for  the MSH2 variants were created using
site-directed mutagenesis as detailed in the original articles.
Production of expression vectors for human cell expression
For protein expression in human cells, WT and mutated MSH2 cDNAs were cloned from
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and NotI restriction sites, so that the red fluorescent protein was replaced by the insert.
The WT MSH6 cDNA was cloned from pFastBac1 into the expression vector pEGFP-N1
(BD Biosciences) between the BamHI and NotI  restriction  sites,  replacing  the  enhanced
green fluorescent protein (EGFP) gene. The resulting constructs expressing MSH2 (WT or
mutated) and MSH6 (WT) were named pMSH2-N1 and pMSH6-N1, respectively.
Baculoviral expression of MutS  variants
The recombinant proteins were produced in Spodoptera frugiperda 9 (Sf9) insect cells
using the Bac-to-Bac baculovirus expression system (Invitrogen). The cDNAs of WT
MSH6, WT MSH3 and WT and mutant MSH2 were transferred to baculovirus vectors via
a transposon-mediated reaction in DH10Bac E. coli cells (Invitrogen). The bacmid DNAs
were isolated from bacterial cultures and the baculovirus DNAs, containing the desired
cDNA inserts, were used to transfect Sf9 cells. The secreted baculoviruses were collected
after 3 days and amplified in Sf9 cells for 5 days. For protein production, Sf9 cells were
co-infected with MSH2 and MSH6 baculoviruses, since the functional MutS -complex
requires both proteins and MSH6 is unstable without MSH2 (Chang et al. 2000, Marra et
al. 1998). For control experiments, cells were coinfected with WT MSH2 and WT MSH3
baculoviruses for MutS  dimer production. The total protein extracts (TEs) including the
heterodimeric MutS or MutS were extracted in lysis buffer (25 mM Hepes, 2 mM -
mercaptoethanol, 0.5 mM spermidine, 0.15 mM spermine, 0.5 mM phenylmethylsulfonyl
fluoride (PMSF), and 2 x Complete protease inhibitor mixture (Roche)). 10% glycerol and
110 mM NaCl were added and the protein extracts were rotated for 30 min at +4°C and
then centrifuged for 50 min at 13200 g. The soluble protein fractions, containing the
recombinant MutS  proteins, were aliquoted and stored at -80°C.
MutS  expression in human cells
Production of recombinant MutS  (heterodimer of MSH2 and MSH6) variants in the
LoVo human colon adenocarcinoma cell line (MSH2-/-) (American Type Culture
Collection) was performed as follows: a total of 200 000 cells were seeded (in one well of
a 6-well plate), and transfected after 24 hours with 2 g of pMSH2-N1 (WT or  mutant)
and 2 g pMSH6-N1 vectors using 8 L of Tfx-20 transfection reagent (Promega). After
48 hours from transfection, the cells were collected by trypsinisation. The total protein
content was extracted by incubating the cells for 25 min on ice in 50 l of cold extraction
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buffer (50 mM Tris-HCl pH 8.0, 350 mM NaCl, 0.5% Nonidet-P40, 1 x complete protease
inhibitor mixture). The suspension was centrifuged at 13200 g for  5  min  at  4°C,  after
which the supernatant, containing the desired recombinant proteins, was collected.
Western blot and coimmunoprecipitation analyses
The expression levels and correct sizes of the recombinant proteins were examined by
sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot
analyses.  The  protein  complexes  were  run  in  6%  SDS-PAGE  gels,  blotted  to  nylon
membranes and detected with anti-MSH2 (MSH2 Ab-2, NA27, Calbiochem, 0.4 g/ml in
insect cell and 0.1 g/ml in human cell expression) and anti-MSH6 (MSH6/GTBP, Clone
44, BD Transduction laboratories, 0.17 g/ml in insect cell and 0.5 g/ml in human cell
expression) antibodies. The amount of naturally expressed -tubulin protein (clone 5H1,
anti- -tub; BD Biosciences, 0.5 g/ml) was used as loading control when the expression
levels of MutS  variants produced in LoVo cells were compared.
The interactions of MSH2 variants with their counterpart MSH6-WT were studied
by combined coimmunoprecipitation and Western blot analysis. For immunoprecipitation,
30 – 100 g of Sf9 TEs were adjusted to contain similar amounts of recombinant proteins.
The protein extracts were rotated for 3 hours (III, IV) or overnight (II) on a rotating wheel
with 1 g of anti-MSH6 antibody (see above) in RIPA buffer (150 mM NaCl, 1% Nonidet
P-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-Cl pH 8.0). A total of 30 l of
protein A/G agarose beads (SC2003, Santa Cruz Biotechnology) were added and the
rotation was continued for 1 (III, IV) or 3 (II) hours. The agarose beads, containing the
precipitated antibody-protein complexes, were collected by centrifugation and washed
three times with RIPA buffer. The precipitated complexes were detected by Western blot
(see above) and the amounts of mutated MSH2 proteins in the precipitates were compared
to WT MSH2.
Protein purification (III-IV)
Fast protein liquid chromatography
WT MutS  and the variants T33P, A636P, E749K, A834T and V923D were purified with
fast protein liquid chromatography (FPLC). The TE was first loaded to the Heparin
HiTrap  column  (Amersham  Biosciences)  and  eluted  with  a  NaCl  gradient  from  300  to
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1000 mM. The fractions containing MutS were loaded onto a MonoQ anion exchange
column (Amersham Biosciences) and eluted with a NaCl gradient from 150 to 550 mM.
The MutS -containing fractions were pooled and dialyzed at +4°C for 2 hours against 25
mM HEPES (pH 7.6),  1 mM EDTA, 110 mM NaCl,  10% sucrose,  3 mM DTT, 0.5 mM
PMSF and 1 g/ml leupeptin. The purified proteins were aliquoted, frozen with liquid
nitrogen and stored at -80°C. The WT MutS  purified with FPLC is hereafter referred to
as WT-FPLC.
Ni-NTA affinity chromatography
The variants N127S, A272V, V161D, G162R, G164R, L173P, L187P, G322D, C333Y,
D603N, G674A, C697F, Del 745-746, and WT MutS  (WT-his), were purified with Ni-
NTA (nitrilotriacetic acid) agarose matrix (Qiagen), which binds the (His)6-tag located at
the N-terminus of the MSH6 subunit of MutS . This approach has previously been
successfully used to purify recombinant MutS  (Gradia, Acharya & Fishel 1997b), and
being fast and simple to perform, it was chosen as the method of purification for the
majority of the proteins. For purification of the MutS  complexes, 100 l of Ni-NTA
matrix (Qiagen) was used for every 1 ml of TE. The matrix was equilibrated with PBS and
mixed with TEs. The mixtures were rotated at +4°C for 2 hours and loaded into 1.5 ml
polypropylene columns (Qiagen). The MutS -bound matrix was washed with wash buffer
(25mM HEPES, 300 mM NaCl, 20mM imidazole, 1 g/ml leupeptin, 1x complete EDTA
free, 0.5 mM PMSF) and MutS  was eluted with an increasing imidazole concentration.
The MutS -containing fractions were pooled, dialysed and aliquoted as described above.
The purities of all different MutS  preparations, purified with both methods, were
compared by SDS-PAGE and coomassie staining, and the concentrations were assessed
with the Bradford assay, using bovine serum albumin (BSA) as a standard.
Mismatch repair assays (I-IV)
Preparation of MMR assay substrates
The DNA substrates used in the in vitro MMR experiments were pGEM 13Zf+ (Promega)
plasmid-derived double-stranded circular heteroduplex DNA molecules, which contained
a G•T mismatch or an extrahelical T insertion within the BglII  restriction  site,  and  a
single-strand nick 370 bp 5’ of the mismatch site in the repairable strand (Figure 6). The
47
plasmids were a kind gift from Professor Josef Jiricny. The substrates were named 5’G•T
and 5’IDL1, respectively. Both of these are efficiently recognised by MutS  and have
been shown to be functional MMR substrates in vitro (Thomas, Roberts & Kunkel 1991a).
The mismatch and nick were designed to give rise to a complete double-stranded BglII
restriction site upon a successful mismatch repair reaction. For linearisation of the
plasmid, a BsaI digestion site, 1360 bp from the BglII site, was used.
Figure  6.  The  substrates  used  in  the  in  vitro  MMR assays. Left:  5’G•T  substrate.  The  uncut
(bottom) strand contains a complete BglII restriction site (5’AGATCT), whereas the nicked strand
has  G  in  the  place  of  A,  resulting  in  a  G•T  mismatch.  Right:  5’IDL1  substrate.  The  top  strand
carries a deleted A in the BglII site, creating a 1bp loop in the bottom strand. BanII was used to
linearize the top strand for  a  5’  oriented nick 370 bp from the BglII  site.  Upon correction of  the
mismatch,  using  the  bottom strand  as  a  template,  a  complete  BglII  site  emerges.  BsaI  cuts  both
repaired and unrepaired plasmids 1360 bp from the BglII site, while BglII cuts only the repaired
molecules. Thus, restriction analysis can be used in the evaluation of the repair efficiency.
The substrates were constructed of three nearly identical pGEM plasmids, of which one
(pGEM-TA) contained a complete BglII restriction site (5’AGATCT), whereas pGEM-
delA  carried  a  deletion  of  A  (5’-GATCT)  and  pGEM-CG  carried  a  G  instead  of  T
(5’GGATCT) in its BglII site. The circular strand in the substrate, possessing the complete
restriction site, was amplified from pGEM-TA as single-stranded (ss) DNA with
bacteriophage M13KO7 and isolated with standard procedures. The top strand, derived
from pGEM-GC for 5’G•T or from pGEM-delA for 5’IDL1 substrate, was amplified as
dsDNA and digested with BanII restriction enzyme to achieve double-stranded DNA
which was linearized 370 bp 5’ from the BglII site. The circular ssDNA (from pGEM-TA)
and linear dsDNA (either from pGEM-GC or pGEM-delA) were annealed with a 10-fold
molar excess of ssDNA to maximize the yield of the desired circular heteroduplex
molecule, minimizing the self-annealing of the linear dsDNA. The excess ssDNA and the
5’G•T 5’IDL1
BglII BglII
AG   TCT









linear double-stranded homoduplex DNA were purified with Benzoylated Naphthoylated
DEAE-  (BND)  Cellulose  resin  (Sigma)  and  Plasmid-safe  DNAse  V  (Epicentre),
respectively. Details of the MMR assay substrate preparation are available in
(Baerenfaller, Fischer & Jiricny 2006).
Preparation of nuclear extracts
Nuclear protein extracts (NE) were prepared because MMR occurs in the nucleus and
nuclear extracts contain all the proteins needed for the reaction. LoVo cells were used due
to their intrinsic deficiency in MSH2 expression. First, ~5 x 108 cells were collected,
washed with PBS and swollen in hypotonic buffer (20 mM Hepes, pH 7.9, 5 mM KCl, 1.5
mM MgCl2, 0.2 mM PMSF, 1 x complete EDTA-free protease inhibitor cocktail (Roche),
0.25 g/ml aprotinin, 0.7 g/ml pepstatin, 0.5 g/ml leupeptin) on ice. The cell
membranes were disrupted using a syringe with a narrow gauge (No. 27) needle. The
nuclei were collected by centrifugation and the resulting pellet was suspended in 1/5
volumes of cold extraction buffer (25 mM Hepes/KOH (pH 7.5), 10% sucrose, 1 mM
PMSF, 0.5 mM DTT, 1 g/ml leupeptine). The salt concentration was adjusted to 155 mM
with 5 M NaCl. The mixture was rotated at 4°C for 1 hour and the nuclear debris was
pelleted by centrifugation. The soluble nuclear protein fraction was dialysed for 2 hours
against 25 mM Hepes/KOH (pH 7.5), 50 mM KCl, 0.1 mM EDTA (pH 8.0), 10% sucrose,
1 mM PMSF, 2 mM DTT, 1 g/ml leupeptine. The dialysed extract was centrifuged and
the supernatant aliquoted and frozen in liquid nitrogen. The NEs were stored at -80 C.
MMR assays
The mismatch repair assays were used to compare the repair activity of the mutated
MutS  proteins to that of the WT (I-IV), and to demonstrate the activity of the protein
preparations after purification (IV). 75 g of MSH2-deficient LoVo NE was incubated
with either 4 – 12 g of Sf9 TE, including adjusted amounts of recombinant MutS , or 1
g of purified recombinant MutS  (III-IV). The reaction contained 100 ng of 5’G•T or
5’IDL1 substrate plasmid, 20 mM Tris-Cl (pH 7.6), 110 mM KCl, 5 mM MgCl2, 1 mM
glutathione, 50 g/ml BSA, 0.1 mM of each dNTP, and 1.5 mM ATP. Successful
mismatch repair completed the BglII restriction site. The repair efficiencies were
calculated after a combined BsaI-BglII digestion and agarose gel electrophoresis by
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For bandshift assays, two double-stranded 38bp DNA oligomers were constructed: one
which carried a G•T mispair, and one which was otherwise identical but had an A•T base
pair in the corresponding position. The nucleotide sequence of the invariable strand was 5’
TTT CTG ACT TGG ATA CCA TCT  ATC  TAT  CTA  TAA  AAT  AT  3’,  and   the
complementary strand carried either A or G in the indicated (bolded) position. The
sequences were synthesised as ssDNA by Oligomer. 10 pmol of the invariable (T) strand
was labelled with 32P in a reaction which contained 10 pmol of 32P- -ATP, 100 mM DTT,
1X polynucleotide kinase (PNK) buffer and 7,5 units of PNK (Promega). The reaction was
incubated in 37°C for 45 min, after which further 5 units of PNK was added, and
incubation was continued for 30 min. The labelled ssDNA oligomers were purified using
ProbeQuant G-50 Micro Columns (Amersham Biosciences). The complementary ssDNAs
were annealed in 1:1 ratio by incubating them for 5 min in 95°C, followed by 5 min in
37°C and 30 min in RT. The double-stranded, labelled oligomers were stored in +4°C.
Mismatch binding
Bandshift assays were used to assess the ability of the MutS  variants to bind
heteroduplexed DNA. Corresponding homoduplexes were used as nonspecific DNA
controls. 350 ng (65 nM in total) of each MutS  variant was incubated in 10% glycerol,
100 mM KCl, 25 mM Hepes-KOH (pH 7.5), 1 mM DTT, 0.5 mM MgCl2, 0.1 mM ADP,
75 g/ml BSA, and 60 ng poly-d(I-C) (Amersham Biosciences) for 20 minutes at 37°C
with  25  femtomoles  of 32P-labelled 38 bp double-stranded DNA oligomers, which
contained  either  a  central  G•T  mismatch  (GT  heteroduplex)  or  an  A•T  base  pair  in  the
corresponding position (AT homoduplex).
The binding was visualized by running the reactions in 5% nondenaturing
acrylamide gels, which were dried and exposed to a phosphoscreen (Fujifilm BAS-1500).
The MutS -bound oligomers migrate slower than unbound DNA in the gel, thus giving
rise  to  a  bandshift.  The  data  was  quantified  with  the  TINA  software,  version  2.09  (OY
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Tamro AB), and calculated as percentages of MutS -bound oligomers of the total amount
of labelled DNA.
Mismatch release
MutS  dissociates from DNA mismatches as a consequence of a conformational change,
which follows adenine triphosphate (ATP) uptake, when ATP replaces an ADP molecule
in  the  ATP-binding  motif  of  MutS  subunits.  To  study  the  ability  of  MutS  variants  to
undergo ADP-ATP exchange and to dissociate from G•T mismatches, ATP was added to
the bandshift reactions at different concentrations (0.5, 1 and 2 mM) after 10 minutes of
incubation, followed by another 10 minutes at 37°C. The concentrations were chosen
based on published data, where the addition of 1 mM ATP results in clear but not 100%
loss of MutS  mismatch binding (Dufner et al. 2000). The fraction of MutS -bound DNA
after ATP addition was calculated as a percentage of the binding level in the absence of
ATP in all experiments.
Statistical analysis
All bandshift experiments were repeated at least four times. The binding data were
analyzed in SPSS, version 12.0.1. by one-way ANOVA, followed by a Tukey post hoc
test. The level of statistical significance was set at 0.05.
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RESULTS
Effects of the studied mutations on MSH2 expression, purification and
interaction with MSH6 (II-IV)
Baculovirus expression revealed variance in the protein levels (II, IV)
We expressed WT and all mutated MSH2 proteins variants with MSH6 WT in Sf9 cells.
Variable expression levels were observed (Table 7, page 56). The MSH2 variants T33P,
N127S, A272V, G322D, A636P, G674A, E749K, A834T and V923E were expressed in
amounts similar to WT MSH2. Although V161D, G162R, G164R, L173P, L187P,
C333Y, D603N, and Del 745-746 were also expressed, their expression levels were <5-
fold lower as compared to the wild-type protein. C697F showed an intermediate level of
expression (~30% of the WT). The amount of MSH6 in the extracts was proportional to
the levels of MSH2, supporting the published observations indicating that MSH6 is stable
only in complex with MSH2 (Chang et al. 2000, Marra et al. 1998).
Human cell expression showed no differences in protein levels (II)
To study the stability of the MSH2 alterations in human cells, we transiently expressed 15
patient-derived MSH2 variants (T33P, V161D, G162R, G164R, L173P, L187P, A272V,
C333Y, D603N, C697F, Del 745-746, E749K, A834T, and V923E) together with WT
MSH6 (MutS )  in  the  LoVo (MSH2-/-) cells. Surprisingly, in human cell expression, all
the studied variants showed comparable amounts of MSH2 to the WT protein (Table 7).
However, in general the human cell expression system did not produce enough protein for
functional studies. Therefore, we used the proteins produced in Sf9 cells for all subsequent
assays.
Protein purification was successful with efficiently expressed MSH2 variants (III, IV)
Both purification methods, FPLC and Ni-NTA, resulted in highly pure WT and most
mutated MutS  complexes (T33P, N127S, A272V, G322D, A636P, E749K, A834T, and
V923E). However, adequate purity was not obtained for the variants present in low
amounts in the Sf9 extracts (V161D, G162R, G164R, L173P, L187P, C333Y, D603N, and
Del  745-746)  (see  above).  It  is  therefore  possible  that  these  variants  are  structurally
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imperfect,  leading  to  either  low  expression  or  insolubility  in  the Sf9 protein extract
preparations and to further degradation during the purification process. These variants
were omitted from the bandshift assays, which required purified proteins. One variant
(C697F) showed an intermediate level of expression and purity and was included in all
experiments (Table 7).
MSH2 G674A impaired the MSH2/MSH6 interaction (II-IV)
We performed combined coimmunoprecipitation and Western blot analysis to study the
effect of the mutations on the interaction of the MutS  subunits, MSH2 and MSH6. MSH2
G674A was observed to impair the interaction, while all other variants interacted with
MSH6  similarly  to  WT  MSH2  (Table  7).  Extracts  derived  from  cells  expressing  the
MutS  complex (MSH2 WT / MSH3 WT heterodimer) gave no detectable signals in the
immunoprecipitation assay, confirming that only MSH6 antibody-bound protein
complexes were present in the immunoprecipitate (see Original Article IV, Figure 3).
Effects of MSH2 mutations on mismatch repair and binding and release of
mismatches (I-IV)
Twelve mutations were MMR-deficient and one showed decreased activity in the in vitro
MMR assays (I-IV)
We tested the ability of the recombinant MutS  variants to complement the MMR-
defective LoVo extracts in repairing of G•T or IDL1 mispairs in vitro and  to  verify  the
activity of MutS  after purification (Table 7). By titrating the amount of the WT MutS
TE  in  the  assay,  we  concluded  that  the  the  amount  of  the  variants  which  were  less
efficiently produced in the Sf9 than the WT was still sufficient for MMR analysis.
Altogether 12 out of 18 MutS  variants appeared completely defective in the MMR assay
(V161D, G162R, G164R, L173P, L187P, C333Y, D603N, G674A, A636P, C697F, Del
745-746, and E749K). T33P showed a reduced MMR efficiency, and the variants N127S,
A272V, G322D, A834T, and V923E showed no deviation from WT in their MMR
activity. The WT MutS  was active in MMR assays after purification with both the
applied methods, FPLC and Ni-NTA, indicating that the protein complexes remained
functional during the purification process.
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Mismatch binding was impaired in two and altered in three variants (III-IV)
The bandshift assays were applied to determine the ability of MutS  variants to bind G•T
heteroduplex oligonucleotides in vitro (Table 7). First, the binding levels of differentially
purified MutS  WT extracts were assessed, and both were found to be active in mismatch
binding. His-tag-purified MutS  bound G•T mismatches with lower efficiency (17.8 ±
7.6%) than FPLC-purified MutS  (31.6 ± 12.2%). Therefore, the binding efficiency of the
analysed variants was always compared to the WT purified with the same method.
Variants T33P, N127S, A272V, G322D, G674A, E749K, and A834T recognised and
bound G•T mismatches at levels comparable to MutS  WT. The variants A272V, G674A,
and V923E showed retained, but compared to the corresponding WT, slightly reduced
binding to heteroduplex oligomers (A272V: 9.3 ± 7.6%, G674A: 11.2 ± 5.1%, V923E:
15.7 ± 6.1%). The A636P variant was deficient in DNA binding (2.3 ± 0.5%), displaying
only weak background binding, similar as to homoduplex DNA. Also the C697F variant
failed to bind the heteroduplex oligomers (1.8 ± 0.4%). The loss of binding activity was
not due to interfering proteins in the C697F extract, as mixed with WT MutS  the C697F
extract did not interfere with mismatch binding (data not shown). When statistical analysis
was applied to the data, only A636P, C697F and V923E showed statistically significant
loss of binding activity (p<0.01). The figures showing the mismatch binding levels are
displayed on the Original Articles III and IV.
Mismatch release was abnormal with MSH2 G674A and E749K mutations (IV)
To study the ability of the MutS  variants to release mismatched DNA upon ATP uptake,
ATP was added to the bandshift reaction (Table 7). Only the mismatch binding-proficient
variants (T33P, N127S, A272V, G322D, G674A, E749K, A834T and V923E) and the WT
proteins were included in the experiment. The DNA binding efficiencies after ATP
addition were quantified and calculated as percentages of the maximum amount of
protein-bound DNA (i.e. binding in the absence of ATP). The WT MutS  dissociated
efficiently already at the lowest used ATP concentration (0.5 mM), where the binding was
reduced to 12.9 ± 6.8% (WT-his) or 12.4 ± 6.2% (WT-FPLC) of the maximum. Adding 1
mM ATP further decreased the binding to 7.2 ± 3.2% (WT-his) and 6.1 ± 2.9% (WT-
FPLC), and 2 mM ATP to 7.1 ± 4.3% (WT-his) and 5.0 ± 3.0% (WT-FPLC). The variants
N127S, A272V, and A834T dissociated from DNA as efficiently as WT protein, whereas
the variants T33P, G322D, and V923E showed slightly reduced release compared to WT
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protein (T33P: 0.5 mM: 21.7 ± 4.5%, 1 mM: 16.8 ± 6.7%, 2 mM: 13.3 ± 5.0%, G322D:
0.5 mM: 23.8 ± 23.7%, 1 mM:  15.3 ± 14.0%, 2 mM: 9.6 ± 7.5%, V923E: 0.5 mM: 29.0 ±
13.3%, 1 mM: 16.1 ± 9.6%, 2 mM: 9.7 ± 8.5%). G674A and E749K displayed reduced
mismatch release at all ATP concentrations, E749K dissociating most aberrantly at highest
ATP concentration as compared to the WT protein (G674A: 0.5 mM: 65.5 ± 21.8%, 1
mM: 47.0 ± 19.5%, 2 mM: 33.6 ± 23.1%; E749K: 0.5 mM: 30.8 ± 21.0%, 1 mM: 21.2 ±
15.0%, 2 mM: 21.1 ± 16.3%). E749K and G674A showed statistically significant
impairment of mismatch release (G674A with all ATP concentrations, p<0.01, and E749K
with 1mM and 2 mM ATP, p<0.05). The figures of mismatch release are shown in the
Original Article IV.
Determination of pathogenicity in MSH2 variants
The final interpretation of the pathogenicity of a variation was made based on both
functional  and  clinical  data  so,  that  the  variants  which  showed  a  clear  functional  defect
and were associated with typical HNPCC phenotype, were interpretated pathogenic.
Variants with no or only minor functional defects and variable clinical data were
interpretated non-pathogenic. All studied mutations, together with the location of the
mutation, fulfilment of AC, IHC result, results of functional tests, and the overall
interpretation of their pathogenicity are collected in Table 8. 12 out of 18 studied MSH2
variants displayed severe defects in the functional assays and were interpreted as
pathogenic. In addition, two displayed slight defects two assays, and their interpretation
was left inconclusive. They may have a milder or no phenotypic effect. Four variants were
functional in all assays or had only a minor alteration in one, and were interpreted as non-
pathogenic.
SIFT analysis compared to functional results of MSH2 missense variants (II, III)
In  our  dataset,  SIFT  predictions  on  tolerability  of  MSH2  amino  acid  substitutions  were
performed  by  our  collaborators  Marc  Greenblatt  and  Phil  Chan  from  the  University  of
Vermont. The SIFT predictions were compared to the pathogenicity of the variants, which
was finally determined using both functional and clinical data. SIFT correctly predicted
the outcome (tolerated or deleterious, corresponding to non-pathogenic and pathogenic) of
thirteen analysed amino acid substitutions (Table 7). Only N127S and A636P SIFT
predictions were not confirmed by the functional data. For variants T33P and V923E, the
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interpretation of their pathogenicity was not clear, due to milder clinical phenotype and
reduced but not absent functionality in MMR assays. T33P was predicted non-tolerated by
SIFT. For V923E, only one (otherwise best fitted) comparative sequence alignment
predicted it to be tolerated, while alternative alignments predicted it to be deleterious (II).
The results of all functional assays and the SIFT prediction scores are summarised in
Table 7.
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T33P 1 DNA binding + + + +  +/-  +  + (-) Deleterious / 0.02
N127S 2 Connector NA + + +  +  +  +  Deleterious / 0.01
V161D 2 Connector + - + -  - NA NA Deleterious / 0.00
G162R 2 Connector + - + -  - NA NA Deleterious / 0.00
G164R 2 Connector + - + -  - NA NA Deleterious / 0.02
L173P 2 Connector + - + -  - NA NA Deleterious / 0.00
L187P 2 Connector + - + -  - NA NA Deleterious / 0.00
A272V 2 Connector + + + +  +  + (-)  + Tolerated / 0.79
G322D 3 Levers NA + + +  +  +  + (-) Tolerated / 0.53
C333Y 3 Levers + - + -  - NA NA Deleterious / 0.00
D603N 3 Levers + - + -  - NA NA Deleterious / 0.01
A636P 5 ATPase + + + +  +  - NA Tolerated / 0.20
G674A 5 ATPase NA + - + -  + (-)  -  Deleterious / 0.00
C697F 5 ATPase +  +/- +  +/- -  - NA Deleterious / 0.00
Del745-756 5 ATPase + - + -  - NA NA NA
E749K 5 ATPase + + + + -  + - Deleterious / 0.00
A834T 5 ATPase + + + +  +  +  + Tolerated / 0.10
V923E 5 Helix-turn-helix  +  +  +  +  +  + (-)  + (-) Tolerated / 0.89
All functional assays except for the human cell expression are based on the recombinant proteins produced with the baculovirus system. NA, not assessed.
a, the functional domain in which the mutated amino acid is located. b, +:      expression approximately at the level of WT, -: expression level <20% of
WT.  +/-:  expression  level  about  30%  of  WT.  c,  SIFT  cut-off  score  <  0,05  was  interpretated  as  deleterious.
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Correlation between the functional assays and clinical phenotypes of
mutation carriers (I-IV)
In general, the functional and clinical data correlated well. In summary, MSH2 mutations
V161D, G162R, G164R, L173P, L187P, C333Y, D603N, A636P, G675A, C697F, Del
745-746, and E749K were defective in at least two functional assays and displayed
phenotypic characteristics which supported interpreting them as pathogenic. T33P showed
reduced activity in the MMR assay. V923E exhibited normal MMR activity but reduced
mismatch binding. However, as the functional evidence on their pathogenicity was not
obvious, and the clinical data pointed to a milder than typical HNPCC phenotype, the
interpretation of T33P and V923E was left inconclusive. 10 out of 11 pathogenic
mutations which had available family data were derived from families which fulfilled AC
I or II, although D603N and A636P were also found from AC negative families (Table 5,
p.  41  and  Table  8).  In  contrary,  3  out  of  4  mutations,  which  were  MMR  proficient  and
showed no or only minor changes in mismatch binding or release, N127S, A272V and
G322D, were associated with variable clinical backgrounds and interpretated as non-
pathogenic. In the family carrying the non-pathogenic A834T mutation, an additional
mutation, deletion of exon 8 of MSH2, was found after completion of the functional
studies. This deletion segregated with the cancer phenotype and likely to be the cause for
HNPCC in this family (E. Mangold, personal communication).
Loss or reduction of MSH2 expression in a tumour, as assessed by IHC, was evident in 9
out of 10 studied tumours associated with a pathogenic mutation, proving the loss of
MSH2 expression to be highly indicative of a predisposition to HNPCC. On the other
hand, MSH2 protein was present in three out of four tumours associated with the
functional variants. All variants, which were unstable in the in vitro expression system,
also showed loss of MSH2 in the tumour. E749K was the only variation, which was MMR
deficient and concluded to be pathogenic, but still expressed MSH2 normally.
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Table 8. The clinical and functional characteristics and overall interpretation of the
studied MSH2 mutations.
ACa MSH2 IHCb Repairc Expression Binding Release
T33P - +  + (-)  +  +  +(-) Inconclusivef
N127Sd  -/+  -/+  +  +  +  + Non-pathogenic
V161D + -  -  - NA NA Pathogenic
G162R + -  -  - NA NA Pathogenic
G164R + -  -  - NA NA Pathogenic
L173P + -  -  - NA NA Pathogenic
L187P + -  -  - NA NA Pathogenic
A272Vd  -/+ +  +  +  +(-)  + Non-pathogenic
G322Dd  -/+  -/+  +  +  +  +(-) Non-pathogenic
C333Y - NA  -  - NA NA Pathogenic
D603Nd  -/+ -  -  - NA NA Pathogenic
A636P  -/+ -  -  +  - NA Pathogenic
G674A NA NA  -  +  +(-)  - Pathogenic
C697F + -  -  + (-)  - NA Pathogenic
Del745-756 + -  -  - NA NA Pathogenic
E749K + +  -  +  + - Pathogenic
A834Te + -  +  +  +  + Non-pathogenic
V923E + -  +  +  + (-)  +(-) Inconclusivef
    Clinical data                      Functional data
    InterpretationMH2 mutation
NA: Not assessed. Clinical data is presented in detail in Original Article II. a. Fulfilment of
Amsterdam  Criteria  (AC)  I  or  II.  +:  fulfilled,  -:  not  fulfilled,  -/+:  AC  status  varies  between
associated families. b. Immunohistochemical analysis of MSH2 protein expression in a tumour. +:
MSH2 expressed, -: MSH2 not expressed, -/+: IHC status varies between reported cases. c. in vitro
MMR capability of the mutation. +: functional, -: deficient, + (-): reduced. d. Mutation associated
with variable clinical characteristics. e. In this family, another deleterious MSH2 mutation was
later found and confirmed as the underlying cause of cancer predisposition. f. Variant was




In hereditary nonpolyposis colorectal cancer (HNPCC), frequent surveillance significantly
reduces the mortality of the mutation carriers (Aarnio et al. 1999b, Mecklin et al. 2007)
but identification of the family members at risk requires reliable molecular diagnosis. If a
found mutation is nontruncating, the diagnosis becomes complicated, as nontruncating
alterations appear to be associated with a wide variety of clinical phenotypes, ranging
from normal to highly increased cancer risk (Raevaara et al. 2005). Therefore, reliable
establishment of the functional consequence of a found genetic variation is very important
and facilitates the assessment of the risk of cancer. In this study, 18 nontruncating MSH2
mutations, which had been found in cancer patients, were investigated to gain insight into
their participation in HNPCC tumorigenesis, and to clarify the mechanism by which they
interfere with MMR. The patients displayed a variety of phenotypes, ranging from typical
HNPCC and Muir-Torre syndrome (MTS) characteristics to milder cancer phenotypes in
terms of age at onset or tumour penetrance. We assessed the expression, MMR activity,
mismatch binding, mismatch release, and subunit interaction capabilities of the mutated
MSH2 proteins corresponding to the identified HNPCC-associated MSH2 mutations.
The analyses revealed severe defects in 12 out of 18 studied variants in the
functional assays, and, supported by the clinical data, the respective mutations were
interpreted as the causative reason for the cancer phenotype in the mutation carriers. The
associated families were typical HNPCC families, which mostly fulfilled the diagnostic
AC. Two variants showed retained but clearly reduced activity in at least one assay,
suggesting milder pathogenicity. In the case of T33P, only two affected individuals were
identified, and V923E was associated with an abnormally high age of onset. The
determination of pathogenicity regarding these two variants was left inconclusive in this
work. Four variants were completely functional or displayed only a minor, statistically
insignificant alteration in one assay, suggesting that these are non-pathogenic. The carriers
of these 4 variants displayed a variety of phenotypes, ranging from healthy individuals to
CRC phenotypes, which were, however, often associated with atypical characteristics,
such as MSH2 expression in the tumour. This suggests that the cancers in these mutation
carriers were either not hereditary, or due to other, unidentified MMR gene defects. In
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case of patients carrying the A834T variation, the latter was shown to be true. After
completion of the functional analyses, an exonic deletion in MSH2 found and shown to
cosegregate with the cancer phenotype.
MSH2 L187P and C697F predispose to HNPCC and MTS
Muir-Torre syndrome (MTS) is a condition characterised by the metachronous or
synchronous occurrence of skin and visceral cancers (Cohen et al. 1995, Schwartz et al.
1989), and due to its molecular etiology being connected to germline MMR gene
mutations, it is considered a subtype of HNPCC (Kruse et al. 1998). The functionality of
MSH2 L187P and C697F were studied because of their connection to both HNPCC and
MTS  families  and  the  uncertainty  regarding  the  role  of  their  variations  in  cancer
pathogenesis. At the time of the study (I), only 3 out of 41 MMR gene mutations which
were reported in literature to be linked to MTS were of the missense type. This was in
contrast to HNPCC-associated MMR mutations, of which about 22% are missense
variations (www.insight-group.org). None of the missense mutations associated with MTS
had been functionally assessed in homologous human systems. Thus, the involvement of
these alterations in the tumorigenesis of combined skin and visceral cancers remained
unverified. Therefore, in order to validate the connection of MSH2 missense alterations to
the syndrome and to ensure the molecular defect underlying the cancer phenotype in the
associated families, the functional analysis of the two putatively MTS predisposing
variations  was  considered  of  high  importance.  Molecular  analysis  would  then  allow  the
diagnosis  of  MTS  in  patients  carrying  these  germline  alterations  and  exhibiting  skin
malignancies already before the manifestation of a visceral cancer. The analysis revealed
that missense mutations L187P and C697F in MSH2 completely inactivate MMR, thereby
being the underlying cause of the MSI phenotype and tumour formation in the described
families. Our data demonstrate that, albeit rarely, nontruncating mutations do underlie the
MTS phenotype as well as HNPCC. We suggest that an MSI-positive skin lesion
combined with molecular analysis revealing a missense mutation in an MMR gene should
lead to the functional analysis of the given variation to ensure a solid diagnosis.
61
No evidence for MSH2 N127S and G322D -linked cancer predisposition
N127S (c.380 A>G) and G322D (c.965 G>A) are two of the most frequently occurring
MSH2 variants. They are classified inconsistently in the literature (Table 6, page 42), and
conclusive evidence of their role in cancer predisposition is missing or contradictory. In
some databases they are listed as single nucleotide polymorphisms (SNPs) occurring with
a frequency of 0 – 9,2% (N127S) and 0 – 6,5% (G322D) (www.ensembl.org,
www.genome. utah.edu/genesnps/), and as pathogenic variations in others (www.insight-
group.org, www.missense.org). These contradictory reports and the absence of functional
data on the human proteins led us to study the functionality of MSH2 N127S and G322D
to provide support either for their predisposing or non-predisposing roles in HNPCC
tumorigenesis. The MMR assay, co-immunoprecipitation and bandshift assays did not
reveal  differences  in  their  functionality  as  compared  to  WT  MSH2.  In  G322D,  the
dissociation from mismatches was observed to be slightly reduced, but this was not
statistically significant.
However, as several reports found both N127S and G322D to be associated with
HNPCC families, we performed a systematic literature search to gain a broader view on
the occurrence of these mutations. Furthermore, we looked for reports providing evidence
for additive effects of other MMR mutations found in N127S and G322D carriers. Indeed,
we found that both N127S and G322D frequently coexist with other MMR gene mutations
(Table 6), and that there is evidence suggesting that N127S may have an additive effect in
a family where a truncating MSH2 mutation is the primary cause of HNPCC. In the study
of Tanyi et al. (2006), the occurrence of the truncating mutation together with N127S was
observed to lower the age of cancer onset, as compared to the carriers of the truncating
mutation only. Carriers of only N127S were asymptomatic. This suggests that N127S on
its own does not predispose to cancer, but, in combination with a deleterious mutation, it
may have an additive effect.
Based on literature reports, the non-pathogenicity of G322D is more strongly
established than that of N127S. In a recent population study, G322D was even reported to
occur more frequently in the healthy than in the CRC patient population (Barnetson et al.
2007). However, the reports of cancer patients where G322D is the only found MMR
variant (Table 6) rule out the possibility that this variation could be strictly classified as
clinically non-relevant. Our interpretation is that G322D on its own does not cause MMR
malfunction, and thus most likely does not promote colorectal tumorigenesis.
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The majority of the studied MSH2 variants inactivated MMR
From previous reports by our research group it was evident that a significant proportion of
MLH1 and MSH6 missense mutations do not inactivate MMR (Kariola et al. 2002a,
Kariola et al. 2004, Raevaara et al. 2003, Raevaara et al. 2005). In MLH1, many variants
were functional in the MMR assay but were shown to be unstable, and some variations
inhibited the correct nuclear transport of the protein (Raevaara et al. 2005). In MLH1, 10
out of 34, and in MSH6, 9 out of 11 studied mutations did not show any functional defects,
and the clinical phenotypes of the cancer patients carrying these non-pathogenic mutations
were variable (Kariola et al. 2002b, Kariola et al. 2004, Raevaara et al. 2005). In MSH2,
we found that 12 of the 18 investigated mutations (V161D, G162R, G164R, L173P,
L187P, C333Y, D603N, A636P, G674A, C697F, Del745-746, and E749K) abolished
MMR totally, and one (T33P) caused a moderate reduction in the MMR activity. Five
mutations (N127S, A272V, G332D, A834T, and V923E) had similar repair activity to WT
MSH2. All mutations with absent MMR activity were interpreted as pathogenic, while the
pathogenicity of T33P remained questionable.
Decreased protein expression was associated with MMR deficiency in N-
terminal MSH2 missense mutations
In order to assess the mechanisms behind MMR deficiency, more detailed analyses in the
characterisation of the MSH2 variants were applied. To assess their mismatch-binding and
release capabilities, the MSH2 variants were re-expressed with his-tagged WT MSH6 and
purified. Notably, the variation in expression levels which occurred already in the first
round of protein expression (II) was repeated in the second round (IV), and led to
difficulties  in  purification  of  some  of  the  variants.  Therefore,  we  concluded  that  the
variants V161D, G162R, G164R, L173P, L187P, C333Y, D603N, and Del 745-746 cause
problems in the expression of MSH2 or its stability. C697F was expressed in amounts
lower than the WT but higher than the other unstable variants, and was classified as
moderately expressed. Seven out of nine poorly expressed variants localised to either the
N-terminal connector or lever domains of the MSH2 protein.
The connector domain connects the DNA-binding subunit of MutS  to the rest of
the MutS  heterodimer. It is responsible for the intramolecular interactions and allosteric
signalling between different protein domains (Warren et al. 2007). (Figure 3, p.29). The
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lever domain connects the ATPase domain to the clamp domain, which makes unspecific
DNA contacts. It is believed to communicate signals defining the conformation of the
protein between the ATP- and DNA-binding parts of the protein. Due to the stabilising
and connecting roles of connector and lever domains, it is not surprising that many
mutations situated in those domains led to protein conformation or stability problems and,
thereby, to defective MMR. The only unstable variants situated outside these domains
were C697F and Del 745-746. These mutations are located in the ATPase domain. C697F
displayed moderate stability, and was purified to reasonable purity. The Del 745-746
mutation is a two amino acid deletion and therefore more severe than a missense mutation.
Thus, it is also likely to have a larger effect on the conformation of the protein.
In  agreement  with  our  results,  reduced  stability  of  MSH2  proteins  has  been  also
reported to be the most frequent explanation for MMR deficiency in a recent yeast study
(Gammie et al. 2007). There, 54 HNPCC-associated missense mutations in MSH2 were
constructed in cognate positions in yeast Msh2 and functionally analysed. 50% of the
mutations, predominantly situated in the connector and lever domains of MSH2, were
shown to be associated with reduced stability.
To investigate the expression of the mutant proteins in human cells, 15 variants
(T33P, V161D, G162R, G164R, L173P, L187P, A272V, C333Y, D603N, A636P, C697F,
Del 745-746, E749K, A834T and V923E) were transiently expressed in MSH2-deficient
human colon carcinoma LoVo cells. Surprisingly, all 15 variants were expressed in similar
amounts as WT MSH2. The reason for this discrepancy between insect and human cell
expression remains unclear, but probably reflects the different conditions within the
different cell types and the differences in the mode of overexpression in the separate
systems. However, the half-life of the studied proteins was not assessed, and thus, even
though the human cells expressed them as WT, the stability may still be affected. The
occasionally observed clonal variation in baculovirus expression is unlikely to be the
reason affecting the varying protein levels, as similar results were obtained in two
completely independent rounds of expression. Due to difficulties in transfecting other
MSH2-negative human cell lines, we were not able to exclude the possibility that the
observed behaviour is unique for LoVo cells.
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Pathogenic  mutations  in  the  ATPase  domain  mostly  interfered  with
mismatch binding or release
The mutations studied in this work were distributed along the length of the MSH2
polypeptide, with some clustering observed in the connector and ATPase domains (Figure
4, p. 40). As discussed, the likely reason for the pathogenicity of the N-terminal mutations
in the connector domain was the low expression or instability of the resulting MSH2
protein. In contrast, only 2 out of 7 studied mutations (C697F and Del 745-746) in the
ATPase domain showed reduced expression. Instead, A636P, G674A, C697F, and E749K
showed clearly impaired mismatch binding or release capabilities, as assessed by
bandshift analysis. V923E, which is situated in the helix-turn-helix (H-T-H) motif in the
extreme C-terminus of MSH2, exhibited reduced mismatch binding. As the H-T-H motif
is involved in the ATPase function by stabilising the ATPase domains in MutS  (Warren
et al. 2007), V923E is discussed along with the ATPase site mutations. Furthermore,
A272V and G674A showed minor impairment of DNA binding, and T33P, G322D and
V923E in mismatch release. These slight alterations were not statistically significant.
Since A636P and C697F were completely deficient in mismatch binding, their
mismatch release activities could not be measured, and the mismatch binding problems
were concluded to be the causative reason for their pathogenicity. V923E showed reduced
binding, and although it was MMR-proficient, the weaker binding could indicate a subtle
MMR defect, too mild to be detected in the in vitro assay. However, a mild defect could
explain the relatively high average age of cancer onset in the V923E family (58 years,
Table 5, p. 41). However, in the absence of an in vitro MMR defect, the interpretation of
V923E remains unconclusive. G674A and E749K bound mismatches similarly to the WT,
but their mismatch release was impaired. These two mutations affect the most conserved
amino acid residues in the superfamily of ABC transporter ATPase domains, to which the
ATPase domains of MSH2 and MSH6 belong (Locher 2004). G674A is located in the
Walker  A and  E749K in  the  Walker  B domain,  two of  the  most  essential  regions  of  the
ATPase domain. As proper ATP processing is vital for MutS  function in MMR, these
mutations cause malfunctions in both mismatch binding and release. Defective mismatch
binding is likely to abolish all MMR-mediated functions, as MutS  needs to recognise the
abnormal base to initiate MMR or any other related process, such as apoptosis signalling,
another important activity of MMR proteins.
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Interestingly, it has been proposed that unlike mismatch binding, the ATP
processing activity is not required for apoptosis signalling mediated by MMR proteins. In
three mouse models for MSH2, MSH6 and MLH1, a point mutation introduced into the
respective ATPase domains inactivates MMR, but the cells of the animals undergo
apoptosis in response to alkylating agents similarly to WT cells (Avdievich et al. 2008,
Lin et al. 2004, Yang et al. 2004). The same phenomenon has been observed in yeast
MutS homologs, where certain ATPase mutants inactivated MMR but remained sensitive
to cisplatin, unlike the Msh2 / Msh6-negative strains (Drotschmann et al. 2004).
Therefore, missense mutations in the ATPase site may be of clinical interest due to the
remaining apoptosis signalling activity, and might result in unaltered responses to certain
anti-tumour therapies, such as cisplatin or temozolomide, which in general are not
effective in MMR-defective tumours (Stojic, Brun & Jiricny 2004).
MSH2 G674A displayed reduced capability to interact with MSH6
Only one protein variant, G674A, interfered with the MSH2/MSH6 interaction in the co-
immunoprecipitation assay, whereas D603N and V923E, which are in the MSH2-MSH6
interaction regions (Guerrette et al. 1998) did not show a decrease in the interaction. This
is probably explained by the fact that MSH2 and MSH6 have two distinct interaction sites
(codons 378-625 and 875-934 in MSH2) and it has been suggested that the loss of function
in one region would not result in complete loss of heterodimer formation (Guerrette et al.
1998). Thus, it is possible that even if some of the mutations interfered with dimerisation,
MSH2 and MSH6 would not be completely detached and would thus precipitate together.
G674A affects the Walker A domain of MSH2 ATPase site, which makes direct contacts
to the ABC transporter unit of MSH6 (Warren et al. 2007). The amino acid substitution in
the  -helix  may  be  sufficient  to  adversely  affect  the  interaction  of  the  two  proteins.
Notably, the interaction problem became evident only in the co-immunoprecipitation
assay, where a stringent RIPA buffer is used. Under more gentle conditions the dimer
remained stable, as demonstrated by the successful purification of MutS -G674A (IV).
66
Phenotypic characteristics of the mutation carriers correlated with the
functional data
Most of the families displaying the pathogenic MSH2 mutations fulfilled the international
AC  for  HNPCC,  showed  an  early  age  at  cancer  onset,  as  well  as  high  MSI  and  loss  of
MSH2 protein in tumours (Table 5). Concerning the pathogenic mutations, the C333Y,
one D603N family and two A636P families did not fulfil the ACI/II. However, D603N
and A636P are also connected to AC-positive families, and the functional data support the
pathogenicity of these mutations. In C333Y, data of only two individuals was available,
but they both had early-onsed CRC. In the case of T33P, the MMR activity was reduced
but not absent, and the family did not fulfil AC, nor did it show deficient MSH2
expression. However, the MSI status was high. We concluded that the reduced but
partially retained MMR activity correlates with the milder clinical phenotype in the family
as compared to families connected to fully pathogenic variations. However, as the IHC
staining for MSH2 protein carrying T33P mutation was positive, the cancer accumulation
may also be unrelated to this variant. The variant V923E functioned similarly to WT
MSH2 in the MMR assay but displayed lowered mismatch binding. Although the family
carrying this mutation fulfils the AC, the average age at onset is abnormally high for
HNPCC (58 years, Table 5).
Regarding the non-pathogenic variations, tumours in the A272V mutation carriers
showed MSH2 expression, supporting our interpretation of non-pathogenicity. However,
the tumours displayed an MSI phenotype. MLH1 was expressed normally in the tumour of
the A272V carrier, so MLH1 somatic inactivation by promoter hypermethylation, which is
a frequent cause of MSI in colorectal tumours, is also unlikely. The mutation A834T, also
proficient in the MMR assay, has been found in the healthy control population (Genuardi
et al. 1999). However, the clinical phenotype of the mutation carriers showed an early age
at onset as well as high MSI and loss of MSH2 in the tumour. As discussed previously, (p.
60 – 61), an additional, truncating mutation (deletion of exon 8) in MSH2 was found in
the A834T family after the functional studies were conducted (E. Mangold, personal
communication). This suggests that this deletion, rather than A834T, was the causative
reason of HNPCC phenotype in the investigated family. The phenotypic characteristics of
the N127S and G322D mutation carriers were discussed in detail above.
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IHC as a screening tool for HNPCC
In our set of MMR-deficient MSH2 variants, MMR deficiency was mainly associated with
typical HNPCC characteristics, among them loss of MSH2 protein in the respective
tumours. Only one tumour, which was associated with the pathogenic mutations, E749K,
showed MSH2 expression in IHC analyses. One, T33P was only mildly defective in the
MMR assay, and thus it is possible that it is not the reason for cancer predisposition in the
family. Unlike T33P, E749K showed complete MMR deficiency, defective mismatch
release and a remarkably young age at onset (29 years) in the mutation carrier, reflecting
the strong mutator effect caused by the mutation.
E749K is located in a highly conserved Walker B domain in the MSH2 ATPase
region and it was shown in our analyses to impair ATP-provoked mismatch release. Thus,
we suggest that the mode of MMR impairment connected to this mutation is the
abnormally strong binding to mismatches, which may lead to defects in the recruitment of
the downstream MMR machinery, which is known to require ATP hydrolysis (Dufner et
al. 2000, Iaccarino et al. 1998). The above mode of pathogenicity may explain the
retained expression of the MSH2 protein in the tumour. This result demonstrates, that
certain ATPase mutations in MSH2 may be, although pathogenic, not identifiable by IHC
analysis. The finding is also supported by the report of the missense mutation T1217D in
the ATPase domain of mouse MSH6. This mutation is MMR-deficient, but expresses
MSH6 protein in the tumour (Yang et al. 2004), although pathogenic MSH6 mutations
usually associate with loss of protein expression (Hampel et al. 2005). Unfortunately, data
for MSH2 expression in the tumours of MSH2 G674A mice, or patients carrying the
MSH2 G674D mutation, are not available.
In conclusion, our data suggests that some ATPase site mutations in MSH2 are not
identifiable with IHC, although overall the correlation between the absence of staining for
MSH2 and pathogenicity of the missense mutation was notable and supports IHC analysis
as a sensitive method in HNPCC diagnostics with MSH2 mutations.
Classification of nontruncating MSH2 mutations
In light of investigations by us and others, it seems evident that the prevailing system of
classification of nontruncating MMR (and other genetic) variants to pathogenic and non-
pathogenic is an oversimplification and does not reflect the real situation where a missense
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mutation may compromise the function of the protein in a significantly different way than
a truncating mutation. For example, some missense mutations in MLH1 lead to mild
HNPCC  phenotypes  in  regard  to  cancer  penetrance  or  age  at  onset  (Peltomäki,  Gao  &
Mecklin 2001, Raevaara et al. 2005). Also, low levels of MLH1 are enough for MMR, but
not sufficient for MLH1-mediated cell cycle arrest (Cejka et al. 2003). Accordingly,
shortage of the mutated protein, rather than its MMR deficiency, has been postulated as
the mechanism of pathogenicity in an HNPCC family with a nontruncating MLH1
mutation (Raevaara et al. 2004). Furthermore, many MMR gene variants have been
reported as both pathogenic and neutral (www.insight-group.org). This suggests that other
MMR gene variations in the affected individuals, or the genetic background in general,
may in combination with the nontruncating MMR gene variant raise the risk of cancer.
Thus, in many cases it is simply not possible to evaluate the phenotypic
consequences of a nontruncating variation based on any single parameter. The combined
use of tumour studies, segregation analysis, population data, conservation of the amino
acids in question, and functional analysis provide the most reliable assessment of
pathogenicity. If both population and functional data support the non-pathogenic
interpretation,  the  variant  probably  does  not,  at  least  on  its  own,  contribute  to  familial
cancer. A functionally deficient mutation for which there is positive data showing co-
segregation of the mutation and the cancer phenotype can be classified as pathogenic.
However, the mutations which occur in healthy individuals and cancer families alike, or
which are associated with atypical HNPCC characteristics and display only modest
functional defects, could be classified as low penetrance variants.
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CONCLUSIONS
The functional studies on 18 nontruncating variants in MSH2, performed as described in
this PhD thesis, led to following conclusions:
In Muir-Torre syndrome, skin tumours combined with the identification of a
germline MMR gene mutation can provide diagnostic clues for consequent visceral
cancers. Nontruncating MMR gene mutations found in skin cancer patients should
therefore be functionally assessed.
Pathogenicity of MSH2 missense mutations is typically associated with an
impaired repair capability of the mutated protein.
MMR deficiency associated with nontruncating mutations in MSH2 is mediated
through different mechanisms. Those include defective protein expression or
stability, and impaired mismatch binding or release.
Reduced protein expression is predominantly associated to mutations in the
connector and lever domains of MSH2.
Mutations affecting the ATPase domain of MSH2 are mostly stable in vitro, but
display problems in mismatch binding or release.
Mutations classified as pathogenic based on functional assays associate mainly
with typical HNPCC phenotypes in mutation carriers.
Mutations, which display only mild defects in functional assays, may associate
with a milder HNPCC phenotype.
Variants, which act like the WT in functional assays, are associated with variable
clinical phenotypes.
Most pathogenic mutations associate with a lack of MSH2 protein expression in
tumour tissue. However, some pathogenic mutations abrogating the mismatch
release but not protein stability may still retain MSH2 expression. Thus,
immunohistochemical analysis is insufficient to exclude a MMR defect.
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FUTURE PROSPECTS
To supplement the present study, it would be interesting to
Further characterise the stability of the studied MSH2 variants in different human
cell lines and by applying protein half-life measurements
Study the effects of nontruncating MSH2 mutations on the MMR-mediated
response to cytotoxic drugs
Study the effects of nontruncating MSH2 mutations on the subcellular localisation
of the protein
Characterise the impact of the mutations on MutS -MutL  ternary complex
formation
Study the mutations in complex with MSH3
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